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 ABSTRACT 
The RAS and RHO family proteins contribute to tumorigenesis and metastasis and belong to a 
family of so called CAAX proteins. The membrane targeting and proper function of CAAX 
proteins are dependent on posttranslational isoprenylation by farnesyltransferase (FTase) or 
geranylgeranyltransferase type I (GGTase-I). Inhibitors of FTase and GGTase-I have been 
developed to block RAS-induced cancer, but their utility has been difficult to evaluate 
because of off-target effects, drug resistance, and toxicity. One aim of this thesis was to use 
genetic strategies in mice to define the physiologic importance of CAAX protein 
isoprenylation and to evaluate FTase and GGTase-I as potential anti-cancer drug targets.  
Oncogenic mutations in RAS are common in cancer and result in hyperactive RAS signaling. 
However, a RAS mutation alone is not sufficient for cancer development in humans. Rather, 
cancer arises as a consequence of cooperation between several mutational events. The tumor 
suppressor gene neurofibromatosis type I (NF1) is a RAS-inactivating protein. Thus, loss of 
NF1 also results in hyperactive RAS signaling and this occurs in some types of cancer. It has 
been proposed that NF1 deficiency is functionally equivalent to an oncogenic RAS; but NF1 
may operate in other pathways. It is not clear if NF1 deficiency would be redundant in RAS-
induced cancer development or if the two mutations would cooperate. A second aim of this 
thesis was to define the impact of Nf1 deficiency on the development of K-RAS–induced 
cancer in mice.  
To approach these aims, Cre/loxP gene targeting techniques in mice were used, to 
simultaneously activate an oncogenic K-RAS allele, to induce lung cancer or myeloid 
leukemia, and inactivate the genes encoding FTase and GGTase-I, or Nf1.  
Inactivating the gene encoding the β-subunit of GGTase-I eliminated enzyme activity, 
blocked proliferation and reduced motility of fibroblasts. Moreover, inactivation of GGTase-I 
reduced tumor formation and increased survival of mice with K-RAS–induced lung cancer. 
Finally, several cell types, including lung tumor cells and macrophages remained viable in the 
absence of GGTase-I. 
Inactivating the gene encoding the β-subunit of FTase eliminated farnesylation of HDJ2 and 
H-RAS, prevented H-RAS targeting to the plasma membrane, and blocked proliferation of 
fibroblasts. FTase inactivation reduced tumor formation and increased survival of mice with 
K-RAS–induced cancer to a similar extent as the inactivation of GGTase-I. The simultaneous 
inactivation of FTase and GGTase-I markedly reduced lung tumors and improved survival.  
These data suggest that inhibition of FTase and/or GGTase-I could be useful in the treatment 
of K-RAS–induced cancer. 
In mice, expression of oncogenic K-RAS or inactivation of Nf1 in hematopoietic cells results 
in myeloproliferative disorders (MPDs) that do not progress to acute myeloid leukemia 
(AML). However, the simultaneous inactivation of Nf1 and activation of oncogenic K-RAS in 
hematopoietic cells induced AML in mice. The levels of active RAS were not increased in 
mice with AML, raising the possibility that Nf1 deficiency may contribute to AML by non-
RAS pathways.  
This result points to a strong cooperation between Nf1 deficiency and oncogenic K-RAS and 
sheds new light on mechanisms of RAS-induced leukemia development. 
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INTRODUCTION 
Everyone knows someone who has been diagnosed with cancer. In Sweden, 50 000 new cases 
are reported every year and around 13% of all deaths in the world are cancer related [1, 2]. 
Although surgery, radiation and cytostatic drugs are still the most common treatment 
strategies today, increased knowledge about the molecular mechanisms governing 
tumorigenesis has resulted in rational design of new drugs.  
One potential drug target is RAS—the most frequently mutated oncoprotein in human cancer. 
Mutations in RAS result in hyperactive RAS signaling. Hyperactive RAS signaling can also 
be caused by mutations in genes that interact with RAS, such as the tumor suppressor gene 
neurofibromatosis type I (NF1). Although knowledge about the biology of RAS proteins is 
increasing, we do not yet fully understand the physiologic and therapeutic importance of the 
posttranslational processing of RAS, or the ability of RAS to cooperate with other mutations 
in cancer development. An overall goal of my thesis is to shed some light on those issues.  
CAAX proteins are involved in the pathogenesis of cancer 
RAS belongs to the family of CAAX proteins. CAAX proteins terminate with the amino acid 
sequence C-A-A-X, where “C” is a cysteine, “A” is often an aliphatic amino acid, and “X” can 
be any amino acid. The family of CAAX proteins consists of more than hundred members [3]. 
RAS is perhaps the most well known CAAX protein involved in cancer development, but 
several other CAAX proteins also contribute to tumor development and progression (e.g. 
RHOA, RAC1, CDC42, RALA, RHOC), by both RAS-dependent and RAS-independent 
mechanisms [4-9]. Table 1 lists the CAAX proteins discussed in this thesis and summarizes 
their normal functions and potential roles in cancer.  
Table 1. CAAX proteins 
Protein Function Cancer association CAAX F GG
H-RAS GTPase/Signal transduction Oncogene (point mutations) , transformation CVLS F
RHEB GTPase/Signal transduction Overexpressed in tumor cells CSVM F
CENP-E Mitotic protein/kinetochore-microtubule attachments CKTQ F
CENP-F Mitotic protein/kinetochore-microtubule attachments CKVQ F
RND1 GTPase/Organization of actin cytoskeleton CSIM F
RND2 GTPase/Organization of actin cytoskeleton CNLM F
RND3/RHOE GTPase/Organization of actin cytoskeleton Cell type-dependent effects CTVM F
HDJ2 Cochaperone/Protein folding CQTS F
Prelamin A Processed to Lamin A and C/Nuclear lamina CSIM F
PRL1 Tyrosine phosphatase/Cell growth and mitosis Progression, motility and invasion CCIQ F GG*
PRL2 Tyrosine phosphatase/Cell growth and mitosis Progression CCVQ F GG*
PRL3 Tyrosine phosphatase/Cell growth and mitosis Progression, motility and invasion CCVM F GG*
K-RAS GTPase/Signal transduction Oncogene (point mutations) , transformation CVIM F GG**
N-RAS GTPase/Signal transduction Oncogene (point mutations) , transformation CVVM F GG**
RHOB GTPase/Endocytic trafficking Tumor suppressor CKVL F GG
RHOH GTPase/Signal transduction in hematopoetic cells Tumor suppressor CKIF F GG
RHOA GTPase/Actin cytoskeleton, migration, trafficking etc Overexpressed in tumors, RAS transformation CLVL GG
RHOC GTPase/Stress fibers, focal adhesions, trafficking Overexpression, invasion and metastasis CPIL GG
RAC1 GTPase/Cytoskeleton, transcription, proliferation, migration Overexpression and mutations, RAS transformation CLLL GG
RAC2 GTPase/Cytoskeleton, transcription, proliferation, migration Overexpressed in tumors CSLL GG
RAC3 GTPase/Cytoskeleton, transcription, proliferation, migration Overexpressed in tumors CTVF GG
CDC42 GTPase/Actin cytoskeleton, proliferation RAS transformation CVLL GG
RALA Vesicle trafficking, cell morphology, motility, transcription RAS transformation, invasion and metastasis CCIL GG
RALB Vesicle trafficking, cell morphology, motility, transcription Cell survival, invasion and metastasis CCLL GG
RAP1A Proliferation, differentiation, adhesion, polarity, migration Cell type-dependent effects on proliferation, metastasis CLLL GG
F = farnesylation, GG = geranylgeranylation
* Weak substrate for GGTase-I when FTase is inhibited
** Substrate for GGTase-I when FTase is inhibited
Overexpressed in tumors
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CAAX proteins undergo posttranslational modifications 
The CAAX motif triggers three posttranslational modifications: isoprenylation, 
endoproteolysis and methylation (figure 1). These modifications increase membrane affinity, 
promote protein-protein interactions and can affect the stability of CAAX proteins [10-12]. 
Moreover, many CAAX proteins need a second signal to acquire a stable membrane 
association, such as palmitoylation of upstream cysteine residues or the presence of a 
polybasic sequence [13, 14].   
CAAX
CAAX
C
C-CH3
3. Methylation
1. Isoprenylation
2. Endoproteolysis
- AA
X
FTase GGTase-I
CAAX
C
C-CH3
- AA
X
RCE1
ICMT
RCE1
ICMT
H-RAS
CENP-E
RHEB
RHOA
RHOC
RAC1
 
Figure 1. CAAX proteins undergo three posttranslational modifications that render them hydrophobic. 
Immediately after translation, CAAX proteins are isoprenylated in the cytosol by farnesyltransferase (FTase) or 
geranylgeranyltransferase type I (GGTase-I). Isoprenylated CAAX proteins are targeted to the endoplasmic 
reticulum (ER), where RAS-converting enzyme 1 (RCE1) and isoprenylcysteine carboxyl methyltransferase 
(ICMT) are located. RCE1 is an endoprotease that cleaves off the - AAX amino acids. Finally, the newly exposed 
isoprenylated cysteine (C) is methylated by ICMT. The modified CAAX proteins are then transported by various 
routes to their subcellular locations. 
Isoprenylation  
Isoprenylation1 is the covalent attachment of either a farnesyl or a geranylgeranyl isoprenoid 
lipid to the cysteine residue of the CAAX motif. Isoprenylation of CAAX proteins is catalyzed 
by FTase and GGTase-I.  
Isoprenoid lipids are intermediates in the cholesterol synthesis pathway 
The 15-carbon isoprenoid farnesyl-pyrophosphate (farnesyl-PP) is an intermediate in the 
cholesterol synthesis pathway (figure 2, page 11) and studies of this pathway led to the 
discovery of protein isoprenylation in mammalian cells [13]. The rate limiting step in 
cholesterol synthesis is the formation of mevalonate from 3-hydroxy-3-methylglutaryl-CoA 
(HMG-CoA), which is catalyzed by HMG-CoA reductase. Statins are widely used drugs that 
lower blood cholesterol levels: they block the formation of cholesterol by inhibiting HMG-
CoA reductase.  
                                                            
1 Farnesylation and geranylgeranylation are collectively called isoprenylation, prenylation or lipidation. In this 
thesis I use the term isoprenylation. 
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But statins affect a variety of cellular functions, such as reducing cell proliferation, and many 
of those effects appear to be unrelated to the lowering of cholesterol. The effect of statins on 
cell proliferation was restored by supplementing the culture medium with mevalonate, but not 
cholesterol. By tracing the added mevalonate, it was found that mevalonate was converted 
into isoprenoids, which were incorporated into proteins [15]. 
 
Acetyl-CoA HMG-CoA
HMG-CoA reductase
Mevalonate
Isopentenyl-PP
Geranyl-PP
Farnesyl-PP
Geranylgeranyl-PP
farnesyl diphosphate synthase
Squalene synthase
farnesyl diphosphate synthase
geranylgeranyl diphosphate synthase
Squalene
CHOLESTEROL
Statins
 
Enzymology of FTase and GGTase‐I 
Mammalian FTase and GGTase-I were first identified and isolated from rat brain cytosol in 
the early 1990: ies [16-19]. FTase and GGTase-I share a common α-subunit, but have unique 
β-subunits (table 2, page 12). In humans, the common α subunit is encoded by FNTA and the 
β subunits are encoded by FNTB and PGGT1B, respectively. It is the β subunits that dictate 
substrate specificity: in general, if the “X” residue of the CAAX motif is leucine, the protein is 
geranylgeranylated; otherwise it is farnesylated [3, 20]. However, there are several exceptions 
to this rule and it is clear that the “X” residue only partially explains the substrate specificity. 
FTase and GGTase-I are relatively selective towards their respective substrates, but there are 
examples of cross reactivity. Proteins with a phenylalanine residue (F) at the “X” position, for 
example RHOH, can be substrates for both enzymes. Also, K-RAS and N-RAS end with a 
methionine (M) and are normally farnesylated by FTase, but when FTase activity is inhibited 
they can be geranylgeranylated by GGTase-I [21, 22]. Additionally, RHOB is a substrate for 
both GGTase-I and FTase, despite the C-terminal leucine [3]. 
Crystal structures of mammalian FTase and GGTase-I, including substrate and product 
complexes, have increased the understanding of reaction mechanisms and substrate specificity 
[20, 23-25]. Both FTase and GGTase-I are zinc metalloenzymes and depend on binding a 
Zn2+ ion for catalytic activity [20]. FTase also requires Mg2+ for full activity [10].  
Figure 2. The cholesterol synthesis pathway. 
First, Acetyl-CoA is converted to HMG-CoA. 
HMG-CoA is converted to mevalonate by 
HMG-CoA reductase; this is the rate-limiting 
step and can be inhibited by statins. 
Isopentenyl-PP is formed from mevalonate, by 
phosphorylation and decarboxylation. Next, 
isopentenyl-PP is converted to geranyl-PP, 
which condenses with another isopentenyl-PP 
molecule to yield farnesyl-PP: both these steps 
are catalyzed by farnesyl diphosphate synthase. 
Finally, squalene is formed by condensation of 
two molecules of farnesyl-PP, catalyzed by 
squalene synthase. Through a series of 
additional reactions squalene is converted to 
cholesterol. In addition, geranylgeranyl 
diphosphate synthase catalyzes the formation 
of geranylgeranyl-PP from farnesyl-PP. 
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Table 2. Characteristics of FTase and GGTase-I  
Farnesyltransferase
(FTase)
Geranylgeranyltransferase type I
(GGTase-I)
Lipid substrate
Protein recognition
motif
Selected protein
substrates
Subunits (mammalian)
Metal requirements
CAAX
X=Ala, Gln, Ser, Met,
Phe
CAAX
X=Leu,
Phe, sometimes Met
RAS, nuclear lamins,
transducin γ subunit,
Rhodopsin kinase,
centromeric proteins
RHOA, RHOC, RAC, RAP
heterotrimeric G protein
γ subunits
α (48 kDa)
β (46 kDa)
α (48 kDa)
β (43 kDa)
identical
25% identity
Zn2+
Mg2+
Zn2+catalysis, protein binding
Farnesyl-PP
15 carbon
Geranylgeranyl-PP
20 carbon
(Adapted from Lane and Beese, JLR, 2006)
Genes
(mammalian)
FNTA (α)
FNTB (β)
FNTA (α)
PGGT1B (β)
 
Genetic characterization of FTase and GGTase‐I  
FTase and GGTase-I have been cloned from a number of non-mammalian species. Studies in 
yeast, fungi, flies and plants yielded diverging results on the impact of disrupting FTase and 
GGTase-I activity. RAM2, a homolog of FNTA, is essential in the yeast Saccharomyces 
cervisiae [26] and in Candida albicans [27]. In contrast, disruption of RAM1, the homolog of 
FNTB, was not lethal but resulted in growth defects [26, 28]. Null mutations in CDC43, a 
homolog of PGGT1B, however, were lethal in yeast [29]. Interestingly, Candida albicans null 
CDC43 mutants were viable, despite the lack of detectable GGTase-I activity, but were 
morphologically abnormal [30]. Furthermore, null mutations in the β subunit of GGTase-I 
were lethal in Drosophila melanogaster [31] but not in Arabidopsis thaliana [32]. Based on 
these different results, it was impossible to predict the impact of FTase and GGTase-I 
deficiency in mammalian cells.    
A few years ago, Mijimolle et al. developed mice with a conditional knockout allele for Fntb 
[33]. In their study, the inactivation of Fntb resulted in embryonic lethality, but the effects in 
adult tissues were very modest. Some findings were clearly inconsistent with previous studies. 
Inactivation of Fntb appeared to inhibit the farnesylation of HDJ2 and H-RAS, but only 
partially, and most remarkably, H-RAS remained in the membrane fraction of cells. They also 
reported that Fntb-deficient fibroblasts grew in culture and that the development of K-RAS–
induced tumors was unaffected by Fntb deficiency. 
These findings were surprising for several reasons. First, several studies had established that 
membrane association of H-RAS is utterly dependent on farnesylation [34, 35]. Second, 
treating cells with FTase inhibitors (FTIs) typically results in cell cycle arrest and, in mouse 
models, FTIs are efficacious against many tumors, including those without RAS mutations 
[36, 37]. Given these unexpected results, we saw an urgent need for reevaluating the role of 
FTase in mammalian cells and in malignant transformation. The consequences of genetic 
disruption of PGGT1B in mammalian cells had not been studied before the work in this thesis. 
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Post­isoprenylation (endoproteolysis and methylation) 
Membrane association of CAAX proteins requires isoprenylation, but the contribution of the 
post-isoprenylation reactions endoproteolysis and methylation are also significant [10, 38]. 
The importance of these modifications for subcellular localization and function of CAAX 
proteins have been studied by members of our lab and others, and are described elsewhere 
[11, 38-43]. Furthermore, our lab defined the impact of Rce1 and Icmt deficiency on K-RAS–
induced myeloproliferative disease (MPD) and lung cancer in mice. Icmt deficiency reduced 
all cancer phenotypes, suggesting that ICMT may be a promising drug target for treating 
RAS-induced cancer [44]. In contrast, Rce1 deficiency surprisingly accelerated K-RAS–
induced MPD development [45]. 
RAS-induced cancer 
The RAS proteins are the most well known CAAX proteins associated with cancer. Mutational 
activation of RAS contributes to tumor formation, progression and metastasis [46]. There are 
three RAS proto-oncogenes2 in humans: HRAS, NRAS, and KRAS. Activating somatic 
mutations in these genes, and also mutations in regulators and effectors of the RAS proteins, 
are prevalent in human cancer, such as pancreas, lung and myeloid malignancies [47].   
The interest in RAS started in the 1960s with the discovery of the Harvey and Kirsten rat 
sarcoma viruses [48, 49]. These retroviruses had hijacked oncogenes from the host (rat) 
genome, which were responsible for the cancer causing activities of these viruses. These 
genes were called Ras (Rat sarcoma) genes (Ha-ras and Ki-ras, respectively) [50, 51]. In 
1982, it was discovered that the retroviral oncogenes had human homologs (named HRAS and 
KRAS) [52-54]. In 1983, a human transforming gene was identified as NRAS, the third 
member of the RAS gene family [55, 56].  
H‐RAS, N‐RAS and K‐RAS have overlapping but distinct functions 
In humans, the three RAS genes encode four highly homologous 21 kDa proteins: H-RAS, N-
RAS, K-RAS4A and K-RAS4B. K-RAS4A and 4B result from alternative splicing of the 
same gene; K-RAS4B is the dominant variant and is referred to in this thesis as K-RAS. RAS 
proteins have the first 85 amino acids in common, which specify binding to GDP and GTP, 
while they diverge at the C-terminal end (known as the hypervariable region). The 
hypervariable region contains residues that target RAS proteins to membranes. All RAS 
proteins are farnesylated at the C-terminal CAAX motif. In addition, RAS proteins need a 
second membrane targeting signal. N-RAS and H-RAS are modified by palmitoylation, while 
K-RAS has a polybasic stretch of lysine residues [57].  
H-RAS, N-RAS and K-RAS have both unique and overlapping functions in different tissues. 
First, the frequency of mutations in the different RAS genes differs and they are associated 
with different types of cancer. Second, genetic studies in mice have shown that K-RAS is 
essential for mouse embryonic development [58, 59], whereas mice deficient in H-RAS and 
N-RAS develop normally and are viable [60, 61].   
The relative importance of the RAS isoforms in different tissues may be explained by 
differences in expression levels. The functional differences between the RAS proteins may 
also depend on the subcellular localization of the proteins [62]. Once the posttranslational 
processing is completed in the ER, palmitoylated N-RAS and H-RAS are transported to the 
plasma membrane by vesicular transport. K-RAS is transported to the plasma membrane via 
                                                            
2 A proto-oncogene is a normal gene that can become an oncogene by mutations or increased expression. 
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an uncharacterized route, perhaps via microtubules [63]. An example of the importance of 
subcellular function is that oncogenic H-RAS has transforming activity when located in ER, 
but not when located in Golgi [64, 65].  
Tight regulation of RAS signaling in normal cells 
RAS proteins act as molecular switches that convert extracellular stimuli (growth factors and 
cytokines) into cellular responses, including proliferation, differentiation and survival (figure 
3) [57, 62, 66]. RAS proteins are small GTPases that cycle between an inactive guanosine 
diphosphate (GDP)-bound and an active guanosine triphosphate (GTP)-bound state. 
Activation of RAS starts with the binding of a ligand to a cell surface receptor, such as 
receptor tyrosine kinases and G-protein–coupled receptors. The activated receptor binds to 
adaptor proteins, which recruit guanine nucleotide exchange factors (GEFs) to the plasma 
membrane, where RAS is located. The association between RAS and GEFs facilitates 
nucleotide exchange on RAS, resulting in replacement of GDP with GTP, which is more 
abundant in the cytosol. GTP-bound RAS has higher affinity for effectors and switches on 
downstream signaling pathways. The signal is rapidly terminated by the inactivation of RAS 
through GTP hydrolysis back to GDP, which is stimulated by GTPase activating proteins 
(GAPs) [57].  
P P
GEF
RAS-GDP
RAS-GTP
GAP
Pi
Receptor tyrosine kinase
Growth factor
Adaptors
RAF
MEK
ERK
Cell-cycle progression
Transcription
PI3K
PDK1
AKT
Survival
TIAM1
RAC
Cytoskeletal organization
Transcription
RAL-GEF
RAL
PLD
Vesicle transport
Cell-cycle progression
Transcription
PLCε
PKC
Calcium signaling
Ca2+
 
Figure 3. RAS signaling pathways. Ligand-bound, activated receptor tyrosine kinases form complexes with 
adaptor proteins, like GRB2 and SHC, which recruit GEFs (e.g. SOS) to the plasma membrane. GEFs stimulate 
the nucleotide exchange on RAS, resulting in increased levels of active GTP-bound RAS. The activation is 
opposed by the activity of GAPs, which ensure that RAS is rapidly inactivated after stimulation. At least six 
different RAS-GAPs exist, including p120GAP and NF1. RAS-GTP interacts with several families of effector 
proteins. The main effector pathways are shown. Numbers 1 and 2 indicate sites for mutations (activating and 
inactivating, respectively) that result in hyperactive RAS signaling.  
INTRODUCTION 
 
15 
 
RAS-GTP binds to and activates several effectors, which activate a diverse set of signaling 
cascades. The RAF-MEK-ERK-signaling pathway was the first RAS effector pathway to be 
characterized and is the one that has been studied the most [62, 67]. Activated ERK stimulates 
transcription factors, which can activate expression of cell cycle regulatory proteins, such as 
Cyclin D.  
Phosphatidylinositol-3 kinase (PI3K) is another well characterized effector of RAS. 
Activation of P13K results in generation of the second messenger PIP3, which activates the 
kinases PDK1 and AKT. AKT promotes cell survival by phosphorylating, and thereby 
inactivating, several pro-apoptotic proteins (e.g. BAD). In addition, PI3K activation 
stimulates RAC, a RHO family GTPase involved in actin cytoskeleton regulation and NF-
κΒ–mediated transcription. RAS can also activate RAC independently of PI3K, by activating 
the RAC-GEF TIAM1 [68].  
RAL-GEFs, such as RALGDS, are yet another RAS effector family. RAL-GEFs stimulate 
RAL, which activates phospholipase D, an enzyme regulating vesicle trafficking. The 
RALGDS pathway has been suggested to also contribute to the inhibition of FORKHEAD 
transcription factors, thereby promoting cell cycle progression and survival. In addition, RAS-
GTP can bind to phospholipase C-ε (PLCε)  leading to calcium release and activation of 
protein kinase C (PKC) [69].  
Hyperactive RAS signaling in tumor cells 
RAS signaling is commonly hyperactivated in tumor cells, which deregulates the downstream 
signaling pathways and results in aberrant cell growth, survival and differentiation [57]. 
RAS mutations: Activating point mutations in RAS occur in 20-30% of human cancers [47, 57, 
66]. RAS mutations are particularly common in pancreatic (60-90%), colon (35-50%), and 
lung cancer (20-30%), and in myeloid leukemia (20-30%) [47, 57]. These point mutations 
cause amino acid substitutions, commonly at codons 12, 13 and 61, which decrease the 
intrinsic GTPase activity or confer resistance to GAPs. In this way, the mutant RAS protein 
becomes locked in the active, GTP-bound state and signals continuously (figure 3, page 14). 
The most frequently mutated RAS gene is KRAS (85%), followed by NRAS (15%) and HRAS 
(<1%) [66]. K-RAS mutations are common in adenocarcinomas of the pancreas, colon and 
lung [47, 57]. In myeloid leukemia, N-RAS mutations are the most common (but K-RAS 
mutations are prevalent). H-RAS mutations are found in bladder and thyroid cancer [47, 57]. 
Inactivating  mutations  in  GAPs:  Hyperactive RAS signaling can also be caused by loss of 
function mutations in negative regulators, such as GAPs. The gene NFI encodes a RAS-GAP 
and functions as a tumor suppressor [70]. Loss of NFI results in accumulation of GTP-bound 
RAS, due to decreased GTP hydrolysis (figure 3, page 14). Patients with an inherited cancer 
syndrome called NF1 are deficient in one of their two NF1 alleles, and are predisposed to 
develop certain tumors (in which both NF1 alleles are often inactivated). Mutations in NF1 
will be further discussed in subsequent chapters. 
Mutations  upstream  and  downstream  of  RAS: RAS signaling pathways are commonly 
hyperactivated by alterations in upstream growth factor receptor tyrosine kinases. The 
epidermal growth factor receptors EGFR/ERBB1 and ERBB2 (also known as HER2/neu) are 
activated in tumor cells by gene amplification, autocrine or paracrine growth factor 
production, or activating mutations [71]. C-KIT and FLT3 are other growth factor receptor 
tyrosine kinases involved in tumorigenesis. Gain of function alterations, such as point 
mutations, result in ligand-independent activation of these receptors, which can then 
hyperactivate downstream targets, including RAS. C-KIT is involved in several types of 
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malignancies, including different forms of leukemia and FLT3 is one of the most frequently 
mutated genes in acute myeloid leukemia (AML) [72]. Moreover, mutations or amplification 
of downstream RAS effectors are implicated in human cancer development. One example is 
BRAF that is frequently mutated in melanomas, which results in activation of ERK. Deletion 
of the tumor suppressor gene PTEN, resulting in activation of the PI3K pathway, is another 
example [66]. 
Multiple RAS effector pathways contribute to RAS‐induced transformation 
Several of the many RAS effectors are expressed in the same cell types. Furthermore, a 
certain effector is activated differentially by the different RAS isoforms. This, together with 
the extensive cross-talk between RAS signaling pathways and between RAS and RHO 
signaling pathways, add to the complexity of regulating cellular behavior. It is a challenge to 
reveal the contributions of each RAS signaling pathway to RAS-induced cancer.  
RAF was the first RAS effector to be identified and by that time it was believed that all 
consequences of mutations in RAS could be explained by the activation of the RAF-MEK-
ERK pathway. Indeed, activation of MEK and ERK is required for RAS-induced 
transformation of murine cell lines [66]. Also, RAS and B-RAF mutations are found in the 
same type of cancers, in essentially non-overlapping occurrence [67, 73, 74]. However, some 
studies have shown that RAF activation alone is not sufficient for tumor development [67]. 
The discovery of mutations in other RAS effector pathways support the proposal that 
oncogenic activities of RAS are mediated also by RAF-independent signaling [67]. Mutations 
in members of the PI3K pathway have been estimated to be found in up to 30% of human 
cancers [75]. Such mutations are common in breast and colon cancer and include the loss of 
the tumor suppressor PTEN and point mutations in the catalytic subunit of PI3K [76, 77]. 
AKT has emerged as a critical mediator for PI3K signaling in tumorigenesis, due to its role in 
regulating cell survival and cell cycle progression [77].  
The RAL-GEF-RAL pathway is probably also important for RAS oncogenesis, even if the 
details about downstream functions of RAL are still unknown [62]. Studies in rodent 
fibroblasts suggested a contributory, but yet limited, role for RAL-GEFs in RAS-induced 
transformation [78]. In human epithelial cells, on the other hand, the activation of the RAL-
GEF-RAL pathway alone was enough to induce RAS transformation [79]. In addition, 
activation of RAL-GEFs alone resulted in metastatic growth of NIH3T3 cells [80].  
Finally, activation of TIAM1 may be involved in RAS-induced tumor initiation. Much data 
point at an extensive collaboration between different GTPase-regulated signaling pathways in 
controlling cell responses and promoting cell transformation [81]. TIAM1, in its role as a 
RAC-GEF, is one link between RHO GTPases and oncogenic RAS signaling [67].  
Targeting RAS as an anti‐cancer strategy 
The essential role of RAS in cancer makes it an attractive target for anti-cancer therapy. To 
target the RAS protein directly, with drugs that interfere with GTP binding or that restore 
GAP sensitivity, has proven to be very difficult. Attempts are made to directly target gene 
expression of RAS with antisense techniques, but the usefulness of this strategy is not yet 
known [82]. Therefore, much effort has been spent on targeting RAS indirectly by inhibiting 
members upstream or downstream of RAS signaling pathways, or by interfering with RAS 
membrane association. Targeting RAS membrane association by interfering with the 
processing of the CAAX motif is one aim of this thesis.  
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Pharmacologic targeting of CAAX protein isoprenylation  
In 1984, it was found that the C-terminus of RAS was required for membrane association and 
transformation [35]. Some years later it was realized that RAS proteins are farnesylated [83] 
and that farnesylation was required for membrane association and transformation of cells [84-
86]. This was the starting point for the interest in protein isoprenylation as a target for anti-
cancer therapy. Later it became clear that isoprenylation is crucial also for the cellular 
activities of several other CAAX proteins, including geranylgeranylated proteins like RHOA 
[87]. The post-isoprenylation modifications are also important for proper functions of CAAX 
proteins and all four enzymes: FTase, GGTase-I, RCE1 and ICMT are potential anti-cancer 
drug targets. This section describes the development and use of inhibitors against FTase and 
GGTase-I and some of their potential target proteins. I also shortly describe statins, 
bisphosphonates and farnesyl thiosalicylic acid (FTS), which are drugs that interfere with the 
membrane association and proper function of CAAX protein by alternative mechanisms. 
Inhibitors of RCE1 and ICMT, the enzymes required for the endoproteolysis and methylation, 
have also been developed and are described elsewhere (reviewed in [88]). 
FTase inhibitors (FTIs) 
Shortly after the discovery that RAS is farnesylated, the responsible enzyme, FTase, was 
characterized and the search for FTIs began [83]. One class of FTIs is the CAAX 
peptidomimetics, such as FTI-276 and FTI-2148, which mimic the CAAX motif. Several other 
FTIs, including lonafarnib (SCH66336) and tipifarnib (R115777), have been identified 
through library screenings. In early preclinical studies, FTIs blocked tumorigenic growth of 
many different tumor cell lines [36, 89, 90]. In most cases FTIs induced a G2/M cell cycle 
arrest, but some studies reported a G0/G1 arrest or no effect on the cell cycle [36, 90, 91]. The 
ability of FTIs to induce apoptosis seems to be dependent on cell type and on secondary 
events (e.g. serum depletion) [36, 90]. In vivo, FTIs inhibited tumor growth in xenograft 
mouse models [92, 93] and in K- and N-RAS transgenic mice [37, 94]. In H-RAS transgenic 
mice, FTIs even induced tumor regression [95]. Importantly, the antitumor effects of FTIs in 
mouse models have been achieved with minimal toxicity [96].  
FTIs have been evaluated in many clinical trials and have generally been well tolerated; even 
if some adverse side-effects have been reported, including myelosuppression, diarrhea and 
vomiting [36, 82]. However, the antitumor effects of FTIs in clinical trials have been 
disappointing. Good single agent results have been achieved in treatment of hematological 
malignancies, especially myeloid leukemia, but not for treatment of solid tumors [36]. Still, 
for the treatment of solid tumors there are some promising data on combining FTIs with 
chemotherapy.  
One likely reason for the lack of potent activity of FTIs is that K-RAS and N-RAS, which are 
the isoforms most often mutated in human cancers, can be geranylgeranylated in the setting of 
FTI therapy [21, 22]. This alternative isoprenylation may also explain why FTIs are not as 
effective in K-RAS and N-RAS transgenic mice, as in H-RAS mouse models. Nevertheless, 
there is an antitumor effect, despite failure to block RAS isoprenylation, which implicates that 
the FTI activity is due to inhibition of farnesylation of other proteins. The lack of correlation 
between antitumor activity and RAS mutations in human cancer cell lines further supports the 
idea that other CAAX proteins are critical targets for FTIs [92, 97].  
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Potential targets for FTIs: 
In theory, the antitumor effect of FTIs can be explained by the loss or change of function of 
any farnesylated protein(s). Some of the candidate proteins are listed in table 1 (page 9) and 
discussed further below.  
H‐RAS 
All RAS isoforms are normally farnesylated in vivo. However, as mentioned earlier, K-RAS 
and N-RAS are isoprenylated by GGTase-I, when FTase activity is inhibited. In contrast, H-
RAS is exclusively farnesylated and its membrane association can be completely inhibited 
with an FTI, resulting in inhibition of H-RAS–dependent oncogenesis [34]. Consequently, 
tumors harboring H-RAS mutations would be susceptible for FTI treatment, but unfortunately 
H-RAS mutations are very rare in human cancer. However, FTIs also inhibit wild-type H-
RAS, which may have antitumor effects. For example, if RAS signaling is increased due to 
upstream activating mutations, inhibition of wild-type RAS could stop the signals from 
reaching the downstream effectors [36, 98]. Targeting a wild-type RAS isoform may also be 
beneficial in tumors harboring a mutation in another RAS isoform. This idea was suggested 
by Fotiadou et al., which showed that cell transformation required both wild-type K- and N-
RAS, because of distinct downstream signaling branches [99]. In fact, there is growing 
evidence that the RAS isoforms are functionally different, maybe due to their different 
subcellular localizations [57]. 
RHEB 
RHEB (Ras homolog enriched in brain) is a farnesylated small GTPase that activates the 
mTOR signaling pathway and regulates cell growth and the actin cytoskeleton [36]. In 
Drosophila, RHEB is required for cell cycle progression and it is overexpressed in 
transformed cells and human tumor cell lines [36, 98]. FTI treatment (lonafarnib) in cell 
culture completely inhibited RHEB isoprenylation and blocked downstream signaling of 
mTOR [100]. In the same study, lonafarnib enhanced the apoptotic response to the 
chemotherapeutics tamoxifen and taxane, an effect that was abrogated by expressing a 
geranylgeranylated form of RHEB (CSVM → CSVL) [100]. In Schizosaccharomyces pombe, 
a geranylgeranylated form of RHEB reversed the cell cycle defect caused by lack of FTase 
activity. These studies suggest that inhibition of RHEB farnesylation may contribute to the 
antitumor activities of FTIs, either when the FTI is used alone or when combined with other 
chemotherapeutics [36, 98].  
Centromere proteins (CENP‐E and CENP‐F) 
Inhibiting farnesylation of the mitotic proteins CENP-E and CENP-F may also contribute to 
the antitumor activities of FTIs. CENP-E and CENP-F are centromere-associated proteins that 
function in kinetochore-microtubule attachments during mitosis [36, 101]. One study showed 
that lonafarnib depleted CENP-E and CENP-F from metaphase kinetochores, which disrupted 
chromosomal maintenance, resulting in mitotic delay [101]. This was consistent with an 
earlier study demonstrating that farnesylated CENP-F was required for G2/M progression 
[102]. Thus, inhibition of CENP-E and/or CENP-F functions may explain the accumulation of 
tumor cells in the G2/M phase in response to FTI treatment. Also, CENP-F is upregulated in 
head, neck and breast tumors, and may be associated with poor prognosis [103, 104]. 
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RHOB 
RHOB belongs to the family of RHO GTPases and exists in both farnesylated and 
geranylgeranylated forms, the latter being more abundant (70%) [105]. RHOB localizes to 
endosomes and regulates endocytic trafficking [106]. It has been suggested that farnesylated 
RHOB (RHOB-F) and geranylgeranylated RHOB (RHOB-GG) are functionally different; and 
that RHOB-GG, which accumulates in FTI-treated cells has an anti-proliferative activity [36, 
98]. However, other studies argue against RHOB-F as a crucial FTI target. For example, 
RHOB-F was shown to be as potent as RHOB-GG in inhibiting cell proliferation in a human 
tumor cell line [107]. RHOB has even been proposed to act as a tumor suppressor, since it is 
downregulated in human tumors and since it inhibits tumor growth, cell migration and 
invasion. Moreover, RHOB-null mice are more susceptible to carcinogen-induced skin tumor 
formation [5, 108].  
PRL/PTP‐CAAX 
The PRL1, 2 and 3 proteins belong to a family of protein tyrosine phosphatases (also called 
PTP-CAAX), which regulate cell proliferation and mitosis. All three PRL proteins are 
farnesylated, but can undergo some, inefficient, alternative isoprenylation [36]. The PRL 
proteins, especially PRL3, appear to be involved in cancer progression [109]. Expression of 
PRL1 and PRL3 has been shown to promote motility and invasion of adenocarcinoma cells. 
Importantly, treating these cells with FTI-2153 disrupted the subcellular localization of the 
PRLs and completely inhibited invasion and motility [110]. This suggests that PRL proteins 
may be important targets for FTI-mediated antitumor effects, especially in metastatic cancers.  
RND proteins 
The RND (round) proteins RND1, RND2 and RND3 (also called RHOE) are unusual 
members of the RHO family of small GTPases. They are always bound to GTP and are 
regulated by expression, localization and phosphorylation instead of GDP/GTP cycling [111, 
112]. They are named after the rounded morphology and disrupted actin cytoskeleton 
observed in cells overexpressing RND1 and RND3. The RND proteins regulate the 
organization of the actin cytoskeleton. However, it is only RND3 that has been clearly linked 
to cancer [111], even if its role is not clear and probably cell type-dependent. RND3 is 
downregulated in some tumors and upregulated in others. RND3 has been shown to inhibit 
cell cycle progression and RAS-induced transformation, but also to have a pro-survival effect 
and to promote cell migration and invasion [5, 113]. RND proteins are normally farnesylated 
and FTI-treatment did not induce alternative isoprenylation [38]. FTI-treatment disrupted the 
subcellular localization of the RND proteins and reversed the rounded phenotype induced by 
the ectopic expression of RND1 and 3 [38]. However, the effects of FTI-induced inhibition of 
membrane association of RND proteins on cancer development remain to be elucidated. 
GGTase­I inhibitors (GGTIs) 
The isoprenylation of K-RAS and N-RAS by GGTase-I in the setting of FTI therapy was one 
of the reasons for the development of GGTIs. GGTIs might be used in combination with FTIs 
to block the isoprenylation of K-RAS and N-RAS. However, it was hypothesized that GGTIs 
would also be effective on their own, because several geranylgeranylated CAAX proteins, 
such as RHOA, RHOC and RALA, are involved in tumor growth and metastasis [7, 9, 114]. 
In vitro, GGTIs inhibit proliferation of a variety of human cancer cell lines, by inducing a 
G0/G1 cell cycle arrest [115-118]. The G0/G1 arrest may be caused by induction of the cyclin-
dependent kinase inhibitor p21CIP1 [115, 117]. Most GGTIs induce apoptosis to various 
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degrees in vitro [116, 118-123]. In vivo, GGTIs inhibit tumor growth in several mouse 
xenograft models [93, 118, 122, 124, 125]. Treatment with GGTI-2154 and GGTI-2418 not 
only inhibited tumor growth, but also induced regression of breast tumors in H-RAS and Erb2 
transgenic mice, respectively [118, 126]. Some GGTIs induce apoptosis in vivo [122, 126] 
but some do not [125]. Indeed, one concern about the in vivo use of GGTIs is toxicity. In a 
study by Lobell et al., two structurally different GGTIs were toxic, at least at higher doses, 
and caused lethality in mice [123]. On the other hand, other studies have suggested that some 
GGTIs might not be particularly toxic [118, 124-126]. GGTI-2418 recently became the first 
GGTI to be evaluated in a Phase I clinical trial [127]. 
Potential targets for GGTIs: 
GGTase-I is responsible for isoprenylating the majority of the RHO family proteins and most 
isoforms of the γ subunit of heterotrimeric G proteins. So far, there are no reports on 
alternative isoprenylation by FTase in the setting of GGTase-I deficiency or GGTI treatment. 
Therefore, all geranylgeranylated CAAX proteins are potential targets for GGTIs.  
RHOA 
Ras homolog gene family member A (RHOA) is a small GTPase that regulates the actin 
cytoskeleton and the formation of stress fibers. RHOA also affects epithelial polarity, focal 
adhesion, cell-cell adhesion, cell migration, vesicle trafficking and cytokinesis [128, 129]. 
These functions are important in tumorigenesis and aberrant RHOA signaling contributes to 
cancer development. RHOA expression or activity is frequently upregulated in human tumors 
[5]. In fibroblasts, activation of RHOA is necessary for RAS transformation [129-131]. 
Active RHOA downregulates the expression of the cyclin-dependent kinase inhibitors p21CIP1 
and p27KIP1, and downregulation of p21CIP1 levels is crucial for oncogenic RAS to promote 
cell cycle entry. Further, RHOA contributes to epithelial disruption during tumor progression 
and is involved in tumor invasion [129]. However, the precise role of RHOA in tumor 
invasion is not clear: inactivation of RHOA has been shown to both inhibit and promote 
migration and invasiveness, depending on cell type [132, 133].  
Some studies have attributed the antiproliferative effect of GGTIs to loss of RHOA function. 
Geranylgeranylation of RHOA has been shown to be required for its ability to form actin 
stress fibers and focal adhesions, and to promote cell growth and transformation [87]. Also, it 
has been proposed that nongeranylgeranylated RHOA fails to downregulate p21CIP1 and that 
this contributes to the cell cycle arrest caused by GGTI treatment. However, a study by Solski 
et al. showed that cells expressing a farnesylated, and thereby GGTI-insensitive, form of 
RHOA still underwent growth inhibition when treated with a GGTI [134]. This suggests that 
other GGTase-I substrates are likely to be involved in GGTI-mediated growth inhibition.  
RHOC 
The small GTPase RHOC is highly homologous to RHOA and RHOB and contributes to the 
regulation of stress fibers, focal adhesions and endosomal transport [128]. High levels of 
RHOC is found in some human tumors and appears to promote tumor invasion and metastasis 
[5]. Clark et al. used a genetic approach to identify RHOC as essential for metastasis [9], 
which was confirmed by siRNA knockdown of RHOC in vitro [132, 133]. In addition, 
knockout of RHOC in mice did not affect the development of mammary adenocarinomas, but 
drastically inhibited metastasis [135]. These results indicate that inhibition of 
geranylgeranylation of RHOC may contribute to the anti-invasion effects of GGTI treatment 
in human cancer cell lines [132, 136].   
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RAC GTPases 
The RAC subfamily of RHO GTPases consists of RAC1, RAC2, RAC3 and RHOG, which 
are all geranylgeranylated [3, 38, 137]. The RAC proteins are involved in pathways that 
regulate cytoskeletal reorganization, gene expression, cell proliferation and migration. Many 
RAC functions are cell type-specific and include formation of lamellipodia, focal complexes 
and membrane ruffles, cell-cell adhesions, cell motility, and activation of NADPH oxidase 
[106, 128]. Deregulated RAC signaling is implicated in cancer development: RAC1 in 
particular, but to a lesser extent also RAC2 and RAC3, are upregulated in human tumors. 
RAC1 is also one of few RHO GTPases that has been shown to be mutated in tumors [5]. In 
vitro, activation of RAC1 stimulates RAS-transformation and may contribute to cancer cell 
proliferation by promoting cell cycle progression [138-141]. In vivo, RAC1 was shown to be 
required for K-RAS–induced lung tumor development [142] and mice lacking the RAC-
specific GEF TIAM1 developed fewer skin tumors [143]. The roles of RAC proteins in 
cancer invasion are likely to be dependent on cell type and expression levels.  
RAC1 and RAC3 have been suggested to be important targets for GGTIs. Cox and colleagues 
showed that GGTI-2166 treatment inhibited RAC1- and RAC3-mediated membrane-ruffling 
and transformation in NIH3T3 cells. Importantly, expression of GGTI-insensitive 
farnesylated versions of RAC1 and RAC3 rescued both membrane-ruffling and 
transformation [137]. 
CDC42 
CDC42 is a RHO family GTPase that controls organization and rearrangement of the actin 
cytoskeleton, affecting formation of filopodia, cell polarity, migration and chemotaxis [106]. 
Moreover, CDC42 has been implicated in G1 cell cycle progression [144]. Expression of 
constitutively active and dominant negative CDC42 constructs in Rat1 fibroblasts showed that 
CDC42 expression can stimulate anchorage-independent growth and contribute to RAS-
induced transformation [6]. There are conflicting data regarding the role of CDC42 in tumor 
progression and the role of CDC42 in invasion and metastasis is also unclear [5].   
RALA and RALB 
The geranylgeranylated RAS-like (RAL) proteins, RALA and RALB, are small RAS 
GTPases. They participate in several cellular processes, for example vesicle trafficking, 
regulation of cell morphology and motility, and transcription [8, 145]. RALA and B are 
activated by RAL-GEFs (e.g. RALGDS), which are direct effectors of activated RAS. RALA 
and RALB have been found to be hyperactivated in several different tumor samples. 
Inhibition of RALA with RNAi techniques impaired anchorage-independent growth of cancer 
cell lines and reduced RAS-induced tumorigenesis in a xenograft model [7, 146]. Moreover, 
RALA may be important for invasion and metastasis [8, 146]. RALB, on the other hand, may 
be dispensable for RAS-transformation and tumor formation, but may be implicated in the 
survival of tumor cell lines and in invasion and metastasis [7, 8, 146]. A role for RAL 
signaling in survival is supported by a study showing that knocking out RALGDS in mice 
delayed the onset of tumor formation and decreased metastasis, effects that were associated 
with increased apoptosis [147].  
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GGTI studies have suggested that inhibiting the geranylgeranylation of RALA and RALB 
contributes to the antitumor effects of GGTIs. A study by Sebti and colleagues pointed out 
RALB as a crucial target for GGTI-induced apoptosis. They showed that a farnesylated 
RALB mutant made pancreatic cancer cells resistant to GGTI-induced apoptosis. In the same 
study, GGTI-treatment also inhibited anchorage-independent growth, which was rescued by a 
farnesylated RALA variant, suggesting RALA as a target for this GGTI-property [148].     
RAP1 
RAP1 exists in two isoforms (A and B) that belong to the RAS family of small GTPases and 
are exclusively geranylgeranylated [3]. RAP1 regulates ERK-dependent functions 
(proliferation and differentiation) and integrin-mediated functions (cell-cell adhesions, cell 
polarity and migration). The effects of RAP1 signaling on cell proliferation are probably cell 
context-dependent. In fibroblasts, RAP1 both attenuated and stimulated cell growth [149]. In 
mouse hematopoietic progenitors, deficiency in SPA1 (a RAP1 GAP) enhanced RAP1 
signaling and resulted in enhanced proliferation [150]. RAP signaling has been implicated to 
also regulate cancer metastasis [151]. In many studies, detection of nonprenylated RAP1A 
(np-RAP1A) by western blot is used as marker for GGTase-I inhibition [152], but less is 
known about the functional importance of np-RAP1A.  
There are more than 100 CAAX proteins and the antitumor effects of FTIs and GGTIs are 
likely a result of inhibiting several CAAX proteins. However, some of the studies discussed 
above indicate that inhibiting farnesylation or geranylgeranylation of a rather limited set of 
CAAX proteins may explain a great deal of the antitumor effects of FTIs and GGTIs. The 
conditional knockout mice for FTase and GGTase-I presented in this thesis are well suited for 
experiments aimed to reveal these target proteins. 
Combining FTIs and GGTIs 
Because neither an FTI alone nor a GGTI alone inhibits isoprenylation of K- and N-RAS, 
FTI/GGTI combinations and dual prenylation inhibitors (DPIs) have been evaluated. Indeed, 
such treatment has been shown to inhibit K-RAS and N-RAS isoprenylation in vitro [93, 123, 
153]. In vitro, FTI/GGTI combinations or DPIs have resulted in increased anti-proliferative 
effects, compared to using either drug alone [93, 122, 153, 154]. In most cases the combined 
treatment or the use of a DPI resulted in additive or synergistic effects on the rate of apoptosis 
[116, 122, 123], while one study reported only a moderate increase of apoptosis [153].  
The effects of FTI/GGTI combinations differ in vivo. In mice xenografted with human colon 
cancer cells, cotreatment with the GGTI BAL9611 and the FTI manumycin enhanced the 
inhibition of tumor growth and enhanced the amount of cell death [122]. No animal toxicity 
was reported. Similarly, cotreatment with FTI-276 and GGTI-297 was not toxic in nude mice 
with tumor xenografts; however, the cotreatment did not increase antitumor activity above 
what was seen with FTI-276 alone [93]. In contrast, in a study by Lobell et al., treatment with 
distinct FTI/GGTI combinations or DPIs were lethal in mice harboring pancreatic xenograft 
tumors, at doses required to block K-RAS isoprenylation. Importantly, at these high doses the 
GGTI compounds (GGTI-1 and GGTI-2) were toxic also on their own [123].    
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Potential targets of combined FTase and GGTase‐I inhibition: 
Inhibiting both FTase and GGTase-I would potentially block isoprenylation of all CAAX 
proteins, which make any CAAX protein a potential target for FTI/GGTI or DPI treatment. Of 
course, K-RAS and N-RAS may be critical targets, since they are key oncoproteins that 
undergo alternative isoprenylation. On the other hand, as discussed earlier, FTIs and GGTIs 
have antitumor effects regardless of RAS mutation status. Blocking both FTase and GGTase-I 
would also inhibit isoprenylation of CAAX proteins that normally exist in both farnesylated 
and geranylgeranylated forms, such as RHOB and RHOH [38]. Both RHOB and RHOH, 
which functions in signal transduction in hematopoietic cells [155], may act as tumor 
suppressors. RHOH inhibits proliferation and migration and enhances apoptosis [128]. Loss 
of function of RHOH (by mutation) contributes to malignant progression in lymphomas [5]. 
Therefore, inhibition of isoprenylation of RHOB and RHOH may not be expected to have an 
antitumor effect.   
Statins, bisphosphonates and FTS  
Statins are widely used to lower cholesterol levels and to reduce atherosclerosis and 
cardiovascular disease. Statins inhibit the formation of mevalonate, the committed step in 
cholesterol synthesis, resulting in reduced levels of plasma cholesterol. However, statins also 
have many beneficial effects that are unrelated to cholesterol lowering. These effects involve 
improving endothelial function, stabilizing atherosclerotic plaques, decreasing oxidative stress 
and inflammation, and reducing risk of cancer [13, 88, 156]. These effects are thought to be 
mediated by inhibition of the isoprenoids (farnesyl and geranylgeranyl lipids), which are 
cholesterol synthetic intermediates (figure 2, page 11).  
Lower levels of isoprenoid lipids may result in inhibition of protein isoprenylation. The first 
consequence of reduced isoprenoid levels is a reduction of cholesterol synthesis, followed by 
a reduction of geranylgeranyl-PP synthesis. This could result in reduced geranylgeranylation 
of proteins, thereby inhibiting the membrane targeting and proper function of 
geranylgeranylated CAAX proteins. The importance of geranylgeranylated proteins, such as 
RHOA and RAC1, are supported by studies showing that the cholesterol-independent 
phenotypes caused by statin treatment can be restored by the addition of mevalonate or 
geranylgeranyl-PP, but not farnesyl-PP [88]. The ability of statins to induce apoptosis in 
tumor cell lines is well-known and more recently the anti-cancer effects of statins have gained 
attention [13].    
Nitrogen-containing bisphosphonates is another class of compounds that can inhibit CAAX 
protein isoprenylation. Bisphosphonates are used for the treatment of diseases characterized 
by excessive osteoclast-mediated bone resorption, such as osteoporosis and tumor-associated 
osteolysis [157]. Bone resorption is the process by which osteoclasts break down bone and 
release minerals. Nitrogen-containing bisphosphonates inhibit farnesyl diphosphate synthase, 
an enzyme in the cholesterol synthesis pathway (figure 2, page 11). Inhibition of this enzyme 
results in lower levels of farnesyl-PP and geranylgeranyl-PP, which are essential for the 
isoprenylation of CAAX proteins. Loss of isoprenylated proteins may not only account for the 
antiresorptive effect of nitrogen-containing bisphosphonates in osteoclasts, but it may also 
result in antitumor activity. Antitumor effects of nitrogen-containing bisphosphonates have 
been observed both in vitro and in animal models; but in the latter case it is not clear if the 
antitumor effect is due to direct inhibition of protein isoprenylation in tumor cells or if it is a 
result of inhibition of bone resorption per se [158]. 
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FTS is yet another inhibitor that can interfere with CAAX protein function [14]. FTS competes 
with the isoprenoid portion of CAAX proteins for membrane binding sites. FTS was shown to 
inhibit proliferation of both H-RAS transformed Rat-1 cells and K-RAS transformed NIH3T3 
cells [159, 160]. The mechanism of action involves disruption of the binding of farnesylated 
RAS to the plasma membrane. Interestingly, FTS is surprisingly selective towards RAS, and 
especially active RAS. The FTS Salirasib is currently tested in Phase I/II clinical trials. Initial 
results indicate that Salirasib is non-toxic and it is now tested in patients with advanced 
hematological malignancies, pancreatic cancer and lung cancer [14].  
Why are genetic studies of FTase and GGTase-I deficiency 
important? 
Publications about the effects of isoprenylation inhibitors reveal many inconsistent results. 
These differences may be explained by differences in the experimental systems (differences in 
genetic background, cell type, tissue etc), but also by compound-specific and off-target effects 
of different compounds. The inhibitors can differ in their selectivity for the target enzyme. For 
example, GGTI-2166 is 100 fold, whereas GGTI-297 is only 3 fold, more selective for 
GGTase-I over FTase. This could have effects on tolerability: GGTI-298 is actually toxic at 
doses required to inhibit RAP1A isoprenylation, while concentrations of GGTI-2166 that 
block RAP1A isoprenylation are not toxic [124]. As mentioned earlier, one class of GGTIs 
(GGTI-1, GGTI-2) developed by Merck laboratories were lethal in mice [123]. The authors of 
this study suggested that the toxicity was related to GGTase-I inhibition, and that the doses of 
GGTIs used by Sun et al. may have been tolerated because they only partially inhibited 
GGTase-I [93, 123, 124]. However, even a small dose of GGTI-2, that did not fully inhibit 
isoprenylation of RAP1A, was lethal [123], suggesting that the toxicity of this compound is 
an off-target effect. In addition, Sebti and colleagues later showed that GGTI-2154 and GGT-
2418 had potent antitumor activities without causing toxicity, at doses that inhibited RAP1A 
[118, 126]. Further, Tamanoi and colleges showed excellent antitumor activity without 
toxicity using another type of GGTI compound [125]. They suggested the reason for the lack 
of toxicity to be the low dose of drug required to inhibit protein geranylgeranylation, 
compared to other GGTI compounds, such as GGTI-2.  
Lack of selectivity could also be a problem for FTIs. Some FTIs from Bristol-Myers Squibb 
targeted not only FTase but also GGTase-II (the enzyme responsible for geranylgeranylating 
RAB proteins). In addition, some FTIs have triggered production of reactive oxygen species 
(ROS), resulting in DNA damage, which is likely an off-target activity of FTIs [161].  
The compound-specific and off-target effects of FTIs, GGTIs and DPIs have made it difficult 
to determine their utility as anti-cancer drugs. This highlights the importance of using a 
genetic approach to understand the physiologic importance of protein isoprenylation and 
establish whether or not inhibition of the CAAX isoprenylation enzymes could be a useful 
cancer therapy. One of the aims of this thesis was to use genetic strategies in mice to define 
the role of CAAX protein isoprenylation on the development of RAS-induced cancer.  
Lung cancer and myeloid malignancies are associated with 
hyperactive RAS signaling 
The mouse cancer models used in this thesis resemble lung cancer and myeloid malignancies 
in humans. The mice with K-RAS–induced lung cancer form tumors that are similar to 
adenocarcinomas in humans [162]. Lung adenocarinoma belongs to the group of non-small 
cell lung cancer (NSCLC) and is the lung cancer type that has the highest incidence of 
activating K-RAS mutations (approximately 20-30%) [163-166].  
INTRODUCTION 
 
25 
 
In mice, expression of oncogenic K-RAS or inactivation of Nf1 in hematopoietic cells results 
in development of MPD [167-170]. These MPD models resemble human chronic 
myelomonocytic leukemia (CMML) and juvenile myelomonocytic leukemia (JMML). 
CMML and JMML are classified as myelodysplastic syndromes/myeloproliferative 
neoplasms (MDS/MPN), according to WHO (the MPD classification recently changed to 
MPN to reflect the neoplastic nature) [171]. Simultaneous expression of oncogenic K-RAS 
and inactivation of Nf1 in hematopoietic cells in mice resulted in an AML-like disease 
(described in paper III) [170]. The incidence of K-RAS and N-RAS mutations is 
approximately 40% in CMML [172] and 20-25% in JMML [173]. Children with the NF1 
syndrome have an increased risk of developing JMML and 10-25% of the JMML patients 
have acquired a somatic mutation to their remaining wild-type NF1 allele in hematopoietic 
cells [173]. In AML, activating point mutations in N-RAS and K-RAS have been identified in 
approximately 20% of cases [174, 175].  
In order to relate the mouse work of this thesis to the clinical situation in humans, the next 
sections provide some general information about lung cancer and some of the myeloid 
malignancies in humans. 
Lung cancer  
Lung cancer is the cancer that kills most people in the world; the 5 year survival rate is ~14%. 
Approximately 90% of lung cancer cases are related to tobacco use. However, the incidence 
of lung cancer deaths that are not associated with smoking or other environmental factors is 
increasing. Symptoms of lung cancer include cough, coughing of blood, chest pain and 
shortness of breath. However, early stage lung cancer is often non-symptomatic, which means 
that patients are seldom diagnosed before their cancer has reached an advanced stage. Quite 
commonly, lung cancer is detected incidentally when a chest x-ray is performed for a different 
reason. Diagnosis is based on bronchoscopy and histological analysis of biopsies. It is 
possible that computed tomography (CT) can raise survival rates for patients with a high risk 
for lung cancer by allowing early detection [176]. 
Lung cancer is divided into two histopathological classes: small cell lung cancer (SCLC) and 
non-small cell lung cancer (NSCLC), accounting for approximately 18% and 80% of lung 
cancer cases respectively. NSCLC is an aggressive cancer that can be further subclassified 
into squamous cell carcinoma, large cell carcinoma and adenocarcinoma; adenocarcinoma is 
the most common form. The size of the primary lesion and extent of metastasis dictate the 
course of therapy. Early-stage NSCLC is treated with surgery and radiotherapy. When the 
cancer has metastasized, combination chemotherapy is the treatment of choice. The addition 
of concurrent radiotherapy may also add survival benefits. However, most patients become 
resistant to therapy, relapse and die from the disease. Due to the high rate of relapse and toxic 
side effects under the standard therapies, there is a need for new therapeutic strategies. 
Advances in the understanding of the molecular events underlying the development of lung 
cancer have enabled researchers to develop targeted therapies, which are specifically aimed at 
cancer cells. Targeted drugs include protein kinase inhibitors, antisense oligonucleotides and 
antibodies [176].  
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Myeloid malignancies 
Hematopoiesis is the formation of blood cells through differentiation of hematopoietic stem 
cells into mature blood cells (figure 4). Myeloid malignancies are a group of heterogeneous 
disorders of hematopoietic stem and/or progenitor cells that derive from the myeloid cell 
lineage. Similarly, neoplasms that derive from the lymphoid linage are called lymphoid 
malignancies and include lymphomas and lymphocytic leukemias. Myeloid malignancies can 
be subclassified into MPN, MDS, mixed MDS/MPN, and AML. 
http://commons.wikimedia.org/wiki/File:Hematopoiesis_simple.svg (091001)  
Figure 4. Hematopoiesis. Hematopoietic stem cells in the bone marrow are multipotential, which means that 
they can give rise to any of the different types of mature blood cells. Since they can also self-renew, they are not 
depleted.  The common myeloid and lymphoid progenitor cells are committed to their respective pathways and 
further proliferation and differentiation give rise to mature blood cells, which can enter the blood [177]. 
MPNs are characterized by overproliferation of one or more myeloid cell types in the bone 
marrow and the accumulation of these cells in blood. The overproliferating cells retain the 
capacity to differentiate and are therefore maturing. In contrast, MDSs display abnormal 
myeloid differentiation and usually also cytopenias (reduced numbers of some type(s) of 
blood cells). MPNs and MDSs often progress quite slowly, but they are frequently 
transformed into AML, which is likely due to the acquisition of additional mutations [178]. 
The hallmark of AML is an increased number of immature myeloid cells/blasts, which results 
in suppression of normal hematopoiesis [179]. 
JMML is a rare MDS/MPN that mostly affects children under the age of six. Symptoms 
include fever, pallor, skin rash, enlarged spleen, liver and lymph nodes. JMML laboratory 
findings include increased white blood cell counts and monocytosis. Generally the 
hemoglobin level is low and the number of blast cells is generally less than 5%. The bone 
marrow is typically hypercellular with myeloid cells of all stages of maturation. An additional 
criterion is in vitro GM-CSF–hypersensitivity of hematopoietic cells [173, 178, 180]. 
Deregulated RAS signaling seems to be a central event in JMML, given that 70-85% of the 
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children with JMML have mutations in KRAS, NRAS, NF1 or PTPN11. PTPN11 encodes 
SHP2, an adapter protein that relays signals from activated growth factor receptors to RAS. 
Two inherited genetic disorders increase the risk of developing JMML: the NF1 syndrome 
(germline inactivation of one NF1 allele) and the Noonan syndrome (associated with PTPN11 
mutations) [173]. The course of JMML is highly variable, but if left untreated 80% of the 
patients survive less than 3 years. Chemotherapy is ineffective. The only treatment that can 
cure JMML is bone marrow cell transplantation, which can result in long-time survival in 40-
50% of the patients. However the relapse rate is quite high. FTIs have shown some efficacy in 
a phase II clinical trial [173, 180]. 
Similar to JMML, CMML exhibits heterogeneous clinical and morphologic features, varying 
from predominantly myelodysplastic to predominantly myeloproliferative. CMML presents in 
the age of 65-75 years and common symptoms are weakness and fatigue due to anemia, 
bruising and bleeding due to thrombocytopenia, and infections due to leukocytopenia. 
Hallmarks of CMML include persistent monocytosis in the blood, less than 20% blasts in 
bone marrow and blood, and abnormal differentiation in myeloid lineages [173, 178]. Median 
survival is 12-24 months [172, 181]. There is no effective therapy for CMML patients: 
chemotherapy has shown only modest success. Bone marrow transplantation could be 
curative but is not an option for the majority of patients, since they are old [173].  
AML is the most common type of acute leukemia in adults and is diagnosed at a median age 
of 65 years [179, 182]. AML is most often sporadic, but some inherited disorders (e.g. Down 
syndrome), MDS and MPN increase the risk of developing AML [179]. In AML, abnormal, 
immature myeloid cells/blasts accumulate in bone marrow and blood. These leukemia cells 
can outnumber normal white blood cells, red blood cells and platelets, resulting in infections, 
fatigue (from anemia) and bleedings. The leukemia cells can also spread to other parts of the 
body, such as the central nervous system. AML is the diagnosis when at least 20% myeloid 
blasts are found in bone marrow or blood.  
As discussed further in the next section, it has been suggested that two types of mutations are 
required to cause AML: one that enhances proliferation and/or survival of cells and one that 
impairs differentiation [179]. AML is divided into several subtypes with different treatment 
options. In general, prolonged remission or cure is rarely achieved, especially not in older 
people [183]. The most common treatment of AML is chemotherapy. Bone marrow 
transplantation has a very potent anti-leukemic effect, but treatment-related mortality is 
around 20%. Targeted therapies are under development: clinical trials with FTIs and FLT3 
inhibitors are ongoing [179, 183]. 
Cooperating mutations in cancer development and progression 
Cancer development and progression require two or more cooperating mutations. Cancer can 
be defined as an uncontrolled accumulation of abnormal cells, which will form a mass 
(tumor) that can spread to invade distant organs (metastasis). It has been suggested that to 
become a cancer cell a normal cell needs to acquire six capabilities: self-sufficiency in growth 
signals, insensitivity to anti-growth signals, evasion of apoptosis, unlimited replicative 
potential, sustained angiogenesis, and tissue invasion and metastasis [184].  
According to the widely accepted “multistep model of cancer”, these capabilities are acquired 
by a stepwise accumulation of genetic changes, where each change (mutation) confers a 
growth advantage, resulting in the transformation of a normal cell into a malignant cell. This 
hypothesis is supported by statistical analyses suggesting that four to seven rate-limiting steps 
are necessary for cancer to arise. Pathological findings of premalignant “intermediate” lesions 
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also support this hypothesis. In mice, tumorigenesis is likely a multistep process as well, even 
if the number of required mutations may be less [184].  
The cancer platform model is an alternative model that may explain tumor development in 
some cases [185]. According to this model, cancer will arise if a cell simultaneously gains one 
mutation that promotes proliferation (e.g. RAS) and another mutation that blocks cell death 
and/or differentiation (e.g. BCL-2) [185, 186]. This creates a “platform” and subsequent 
interactions between the growing tumor and its environment give rise to additional mutations, 
resulting in the acquisition of the “hallmarks of cancer” [185].  
A similar model has been proposed for hematopoietic malignancies [187]. According to this 
“two-hit” model, acute leukemia arises as a consequence of cooperation between two 
mutations: a class I mutation and a class II mutation. Class I mutations confer a proliferative 
and/or survival advantage and class II mutations impair hematopoietic differentiation. Class I 
mutations include mutations in receptor tyrosine kinases (e.g. BCR-ABL, FLT3), RAS genes 
(NRAS, KRAS), NF1 or PTPN11; the presence of a class I mutation in a myeloid progenitor is 
sufficient to induce myeloproliferative phenotypes. Class II mutations often involve 
chromosomal translocations targeting transcription factors important for normal 
hematopoietic development, for example the fusion genes AML1-ETO and PML-RARα [187, 
188]. Cooperation between class I and II mutations have been confirmed in several mouse 
models of acute leukemia, for example between FLT3 and AML1-ETO in AML [189] and 
between K-RAS and PML-RARα in acute promyelocytic leukemia (APL) [190]. The two-hit 
model is supported by the finding that mutations of the same class often are mutually 
exclusive. AML samples rarely have more than one mutation of each class [188, 189]. 
Similarly, mutations in RAS, NF1 and PTPN11, which all encode components of the RAS 
signaling pathway, seem to be mutually exclusive in myeloid tumors [191, 192].  
Oncogenic RAS and NF1 deficiency  
The non-overlapping pattern of RAS and NF1 mutations supports the idea that NF1-deficiency 
is functionally equivalent with an activating RAS mutation. Heterozygous inactivating 
mutations in NF1 in the germline cause the NF1 syndrome. NF1 is a familial tumor 
predisposition syndrome characterized by pigmented skin lesions and benign neurofibromas. 
Importantly, individuals with NF1 frequently develop certain types of malignant tumors, 
including neurofibrosacroma and the childhood leukemia JMML. Individuals with NF1 also 
display noncancerous symptoms, such as learning disabilities and bone deformations. NF1-
haploinsufficiency seems to be important for the developmental phenotypes, such as learning 
disabilities, and for abnormal growth and differentiation of melanocytes [57, 70]. In 
malignant tumors from NF1 patients and Nf1 haploinsufficient mice, both NF1 alleles are 
often inactivated, indicating that NF1 is a tumor suppressor gene. NF1 is a RAS-GAP and 
suppresses tumor formation by downregulating RAS signaling. Decreased GAP activity and 
increased RAS-GTP levels have been found in NF1-deficient neurofibrosacroma and myeloid 
leukemia cells and tumors, as well as JMML samples from children with NF1 [57, 70, 191, 
193, 194].  
However, other findings suggest that NFI has additional functions, independent of its RAS-
GAP activity, at least in some cell types [70, 191, 194]. In neuroblastoma and melanoma cell 
lines, NF1-deficiency has not been associated with increased RAS-GTP levels [195, 196]. 
Similarly, overexpressing N-RAS in Nf1+/- mice enhanced lymphoma incidence and activated 
ERK, without affecting the RAS-GTP levels [194]. Further, the GAP-related domain 
compromises only 10% of the NF1 protein and many mutations found in NF1 patients occur 
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outside the GAP-related domain [70, 194, 197]. Finally, in Drosophila, NF1 regulates not 
only RAS, but also adenylyl cyclase - cyclic AMP - protein kinase A (PKA) signaling 
pathways. In Drosophila, adenylyl cyclase activity is important for learning and memory, 
neuropeptide response, body size, life span and stress resistance [198-201]. Importantly, 
human NF1 has also been shown to regulate adenylyl cyclase activity and expression of 
human NF1 rescued the phenotypes in the NF1 mutant flies [202]. Finally, Corral et al. 
suggested that NF1 is involved in a RAS-independent pathway that regulates expression of 
focal adhesion kinase, which may affect cytoskeletal organization [203].  
The indications that NF1 is more than a RAS-GAP prompted us to test whether or not NF1 
deficiency was functionally equivalent to oncogenic RAS, by genetically inactivating Nf1 in 
mice with a K-RAS–induced MPD.   
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AIMS OF THE THESIS 
The overall research aims for my thesis were to define FTase and GGTase-I as potential drug 
targets for treating K-RAS–induced cancer, and to define the impact of Nf1 deficiency in K-
RAS–induced cancer. 
 
The specific aims for papers I-III were: 
 To test the hypothesis that inactivation of GGTase-I would inhibit K-RAS–induced cancer 
in mice (I). 
 
 To test the hypothesis that inactivation of FTase, or FTase and GGTase-I, would inhibit 
K-RAS–induced cancer in mice (II). 
 
 To define the impact of inactivating Nf1 on the development of K-RAS–induced MPD in 
mice (III). 
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EXPERIMENTAL STRATEGIES 
Detailed descriptions of methods are found in each of the papers. Here, I describe the genetic 
strategies and mouse models used in the work for this thesis, to provide a better understanding 
of their utilities and limitations.  
Genetically engineered mice3 are powerful tools to study gene function, define mechanisms 
of disease pathogenesis and to test therapeutic strategies for cancer and other diseases. 
Geneticists have used the mouse as a model organism for more than 100 years, but the interest 
increased dramatically 30 years ago with the technique for inserting exogenous DNA into the 
mouse germ line [204-206]. Today, the mouse is the most common experimental animal - 
thanks to the ease of genetic manipulation; similarities to humans in genetics, organ systems 
and physiology; their small size; and quick reproducibility [207, 208]. However, it is 
important to be aware of the limitations of the mouse as a model for human cellular function 
and pathology. There are many differences in cellular processes between mice and humans; 
regarding cancer development, we differ in disease susceptibility, tumor types and 
requirements of genetic changes for cellular transformation [208].  
In transgenic mice, exogenous DNA (encoding a gene-of-interest) is incorporated into the 
mouse genome. Transgenic mice can be produced by viral infection or microinjection of DNA 
into one of the two pronuclei of a fertilized mouse egg [209, 210]. This technique adds 
genetic material and has been extensively used to generate mice that overexpress proto-
oncogenes or activated oncogenes. Such mice have been valuable for obtaining knowledge 
about tumor processes and oncogenic cooperation [211-214], but they also have drawbacks. 
First, pronuclear injection results in random integration of the exogenous DNA into the 
genome and the number of copies vary, which influences transgene expression levels. Second, 
there are issues about ectopic expression of oncogenes (e.g. RAS) from exogenous promoters, 
since this may produce very different results compared to when genes are expressed from 
their endogenous promoters [168, 210]. These limitations were met by the development of 
gene-targeted mice. 
With gene targeting, an endogenous gene can be modified. DNA is inserted at a specific 
genomic locus using homologous recombination4 in embryonic stem (ES) cells [210, 215, 
216]. The gene-targeted ES cells are injected into blastocysts and gene-targeted mice are 
generated. Gene targeting can be used to create “knockout” and “knock-in” mice. In a 
knockout mouse, the gene-of-interest is functionally eliminated, by inserting a construct with 
a null mutation. In a knock-in mouse, the sequence of the targeted gene is changed to modify 
its function (e.g. by insertion of an activating mutation in a proto-oncogene). Transgenic and 
gene-targeted strategies have one problem in common: the introduced genetic alteration 
affects all cells of the animal at all times, including embryonic development [217]. For 
example, homozygous knockout of a vital gene can cause embryonic lethality or severe 
disruption of development, preventing analysis of its function in adult tissues. In addition, 
expression of an oncogene or a knockout of a tumor suppressor gene in the whole mouse does 
not adequately model sporadic tumor development in humans. To address these problems, so 
called “conditional” strategies have been developed, by which activation or inactivation of a 
gene can be induced in a tissue-specific and/or time-controlled manner.   
                                                            
3 Genetic engineering can be defined as a direct manipulation of an organism’s genes. 
4 Homologous recombination is a nucleotide exchange between two similar or identical strands of DNA.  
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One way to achieve conditional gene targeting is to use bacterial or eukaryotic recombinases, 
which catalyze recombination between specific nucleotide sequences. The most commonly 
used recombinase is Cre. Cre has been isolated from bacteriophage P1 and recognizes a 34-bp 
sequence called loxP (locus of crossing “X” over of P1).  The mouse models used in this 
thesis were created using the Cre/loxP system. A similar recombinase system is Flp/FRT. Flp, 
isolated from Saccharomyces cervisiae, catalyzes recombination between FRT (FLP 
recombination target) sites [218].  Another approach to achieve spatial and temporal control is 
the tetracycline (tet)-dependent systems: “tet-on” and “tet-off”. Unlike the Cre and Flp 
systems, this system allows gene expression to be switched on and off at any time, by 
administration or withdrawal of doxycycline [219]. 
Inducible and site-specific gene targeting with Cre/loxP techniques 
Cre/loxP-mediated targeting can be used to create conditional, cell type-specific knockout 
alleles [220]. Homologous recombination in ES cells is used to insert loxP sites (in 
nonfunctional regions of the gene), so that they flank the endogenous gene-of-interest or an 
exon essential for gene function. Cre recombinase recognizes the loxP sites and induces 
recombination between them. The recombination results in deletion of the DNA between the 
loxP sites, producing a nonfunctional allele. Tissue-specific knockout is commonly attained 
by mating the mice containing the “floxed” allele with mice expressing Cre in the desired cell 
type or tissue. Figure 5 (page 33) shows the strategy that we used to knockout our conditional 
Pggt1b allele in a cell type-specific manner. Cre can also be delivered to a specific tissue (e.g. 
liver or lung) by infection with a Cre-adenovirus [162, 221]. Furthermore, gene inactivation 
can be induced at a given time, by using an inducible promoter to control Cre expression, for 
example the interferon-inducible Mx1 promoter [222]. In this way, the gene can be inactivated 
in adult tissues, circumventing potential effects of gene loss on embryonic development.  
Moreover, Cre/loxP strategies can be used to restrict expression of a gene to a specific tissue. 
This can be done by inserting a STOP cassette (a transcriptional terminator sequence flanked 
by loxP sites) between the gene to be expressed and its promoter [223]. In Cre-expressing 
cells the STOP cassette is removed, which switches on expression of the gene. The 
conditional oncogene LSL-K-rasG12D (hereafter designated KLSL), used in this thesis, is an 
example of this strategy [162].   
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Figure 5. Cell type-specific inactivation of Pggt1b using the Cre/loxP system. A mouse with a “floxed” 
Pggt1b allele was created by inserting loxP sites around exon 7, which is essential for gene function. This loxP-
containing mouse was bred with a mouse harboring a Cre transgene, controlled by a cell type-specific promoter. 
In the resulting mouse, Cre is produced only in cells where the Cre promoter is active. In these cells, Cre 
recombines the loxP sites, deleting exon 7 of Pggt1b, which inhibits the production of a functional gene product 
from this allele. In mice that carry the Cre transgene and two copies of the floxed Pggt1b allele, both copies of 
Pggt1b are inactivated and no functional GGTase-I is produced.  
Mouse models for defining the impact of FTase and GGTase­I deficiency on 
lung cancer and myeloproliferation 
In paper I and II we describe the generation and validation of conditional knockout alleles for 
FTase and GGTase-I, designated Fntbfl and Pggt1bfl, respectively. We used mice harboring 
these alleles to define the impact of inactivating Fntb and/or Pggt1b on tumor development in 
two different mouse cancer models.  
Assessing the impact of inactivating Fntb and Pggt1b in KLSLLC mice  
KLSLLC is a model of lung cancer and myeloproliferation and is described in paper I. 
KLSLLC mice carry a copy of the KLSL allele [162]. In the KLSL construct, a KRAS oncogene 
with an activating mutation (G12D) has been inserted downstream of a floxed STOP cassette. 
The KLSL allele is normally silent, but Cre recombinase excises the STOP cassette, switching 
on expression of K-RASG12D. The KLSL allele was produced by a knock-in approach, which 
means that the mutant construct was inserted into the endogenous KRAS locus. Thus, K-
RASG12D is expressed from the endogenous promoter. In addition, KLSLLC mice harbor a 
lysozyme M-Cre (designated LC) knock-in allele. As a result, KLSLLC mice express Cre from 
the endogenous lysozyme M promoter, which is active in granulocytes, monocytes, 
macrophages and type II pneumocytes (lung cells) [224-226], resulting in K-RASG12D 
expression in these cell types.  
The dominant phenotype of the KLSLLC mice was a rapidly fatal lung cancer. The disease 
was 100% penetrant and extremely predictable, with phenotypes that were easy to measure 
(e.g. survival, lung weight). The lethality and full penetrance made the KLSLLC mice well 
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suited for proof-of-concept studies: would inactivation of FTase and/or GGTase-I have an 
impact on K-RAS–induced lung cancer in vivo? To answer this question, we bred KLSLLC 
mice that were homozygous for the “floxed” Fntb and/or Pggt1b alleles (figure 6 outlines the 
typical experimental strategy). In the lung and myeloid cells of these mice, Cre 
simultaneously activated expression of K-RASG12D an inactivated Fntb and/or Pggt1b.  
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Figure 6. Experimental strategy to define the impact of GGTase-I deficiency on K-RAS–induced cancer. 
Pggt1bfl/flKLSLLC mice were generated, in which K-RASG12D was expressed and Pggt1b inactivated in lung 
and myeloid cells. As comparison, littermate Pggt1bfl/+KLSLLC mice, harboring one wild-type allele of Pggt1b, 
were generated; these mice exhibit a fatal lung cancer and mild myeloproliferative phenotypes.  
One drawback with the KLSLLC model was that Cre expression was not restricted to one cell 
type, resulting in the development of not only lung cancer, but also myeloproliferative 
phenotypes. Furthermore, cancer was initiated already in newborn mice. Finally, Cre 
expression was very wide-spread; essentially all lung cells were turned into lung cancer cells; 
in humans only one or a very limited number of cells contribute to the development of the 
primary tumor. Therefore, it was essential to substantiate our findings with another model of 
K-RAS–induced cancer, where Cre expression was induced in only a few lung cells. 
Inactivation of Fntb and Pggt1b in a second K‐RAS–induced lung cancer model 
Lung tumor formation can be induced in adult KLSL mice by inhalation of a Cre-adenovirus 
through the nose. Cre is expressed in the infected lung cells, the oncogenic K-RAS allele is 
activated and tumors develop within 4–6 weeks [162]. By controlling the virus dose and the 
time allowed for tumors to develop, the number and histological grade of tumors can be 
regulated, so to more closely resemble human lung cancer. In our hands, this model was 
100% penetrant, although variations in tumor burden between mice of the same genotype 
were larger than with the KLSLLC model.  
The basis of our genetic strategies is that Cre expression activates K-RASG12D expression, to 
initiate tumor formation, and inactivates the genes encoding the isoprenyltransferases, in the 
same cells at the same time. One general limitation with this experimental strategy is the 
inability to evaluate the impact of inactivating Fntb and/or Pggt1b on already established 
tumors. Nevertheless, this strategy will answer the question of whether tumors would develop 
in the absence of FTase and/or GGTase-I. 
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Modeling myeloid malignancies and oncogene cooperation in mice 
Myeloid malignancies are often associated with hyperactive RAS signaling. In mice, 
conditional inactivation of Nf1 or activation of K-RASG12D expression in hematopoietic cells 
results in a fatal MPD with a long [169] or short [167, 168] latency, respectively. In both 
models, Cre expression is controlled by the interferon-inducible Mx1 promoter, which can be 
activated by injection of pI-pC (a double stranded RNA that induces an interferon response). 
In Nf1fl/flMx1-Cre mice (designated NM), Cre expression inactivates Nf1 in hematopoietic 
cells; in KLSLMx1-Cre (KM) mice, Cre expression activates expression of K-RASG12D from 
its endogenous promoter. Both models exhibit leukocytosis, growth factor hypersensitivity of 
hematopoietic cells, splenomegaly, and infiltration of myeloid cells in the liver—but they do 
not progress to acute leukemia.  
Loss of NF1 has been viewed as functionally equivalent with an activating K-RAS mutation. 
However, in mice, the MPD induced by Nf1 inactivation is much less severe than the K-RAS–
induced MPD. We argued that if Nf1 deficiency and oncogenic RAS mutations were 
functionally equivalent, inactivation of Nf1 should have a limited effect on the development 
of K-RAS–induced MPD. To answer this question, we bred Nf1fl/flKLSLMx1-Cre (NKM) 
mice and injected them with pI-pC. The NKM mice allowed us to define the impact of Nf1 
deficiency on K-RAS–induced MPD.  
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SUMMARY OF RESULTS 
FTase and GGTase-I deficiency reduced tumor development and 
improved survival in mice with K-RAS–induced lung cancer (Paper 
I-II) 
Paper I and II describe the impact of inactivating FTase and/or GGTase-I on normal and K-
RASG12D–expressing mouse embryonic fibroblasts, and on the development of K-RAS–
induced cancer in mice. First, conditional knockout alleles for the β subunits of FTase (Fntbfl) 
and GGTase-I (Pggt1bfl) were created and validated. The Fntbfl allele was validated by 
showing that Cre-adenovirus infection converted Fntbfl/fl fibroblasts to FntbΔ/Δ fibroblasts, 
which lacked expression of Fntb. Furthermore, inactivation of Fntb inhibited isoprenylation 
of the FTase substrates HDJ2 and H-RAS, and blocked membrane targeting of H-RAS. 
Expression of Cre recombinase in Pggt1bfl/fl mouse embryonic fibroblasts converted the 
Pggt1bfl alleles to null alleles (Pggt1bΔ) and blocked GGTase-I activity. Thus, the conditional 
knockout alleles worked as planned. 
Inactivation  of  Fntb  alone  and  Pggt1b  alone  in  fibroblasts  blocked  cell 
proliferation, while simultaneous inactivation induced apoptosis  
Inactivation of Fntb arrested proliferation of primary and immortalized fibroblasts (figure 
7A). FTase-deficient fibroblasts (FntbΔ/Δ) were large and flat, accumulated in the G2/M phase 
of the cell cycle, but remained viable. Western blots showed that p21CIP1 was upregulated in 
primary FntbΔ/Δ fibroblasts compared to primary Fntbfl/Δ fibroblasts (having one functional 
Fntb allele). FTase deficiency also induced a G2/M cell cycle arrest in K-RASG12D–
expressing fibroblasts. 
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Figure 7. Fibroblasts deficient in either FTase or GGTase-I failed to proliferate, and simultaneous 
deficiency in both enzymes induced apoptosis. (A) Equal numbers of primary Fntbfl/Δ fibroblasts treated with 
β-gal (+FTase) and Cre (-FTase) were seeded and subsequently counted at the indicated times. (B) Equal 
numbers of primary Pggt1bfl/fl fibroblasts treated with β-gal (+GGTase-I) and Cre (-GGTase-I) were seeded and 
subsequently counted at the indicated times. (C) Percent apoptotic cells in cultures of Fntbfl/flPggt1bfl/fl 
fibroblasts 4 days after incubation with β-gal– or Cre-adenovirus. β-gal is a virus that does not induce 
recombination and was used as a control.  
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Similarly, inactivation of Pggt1b blocked proliferation of primary fibroblasts (figure 7B, page 
36), but did not affect cell viability. The Pggt1bΔ/Δ fibroblasts were arrested in the G1 phase 
of the cell cycle and accumulated p21CIP1. Furthermore, GGTase-I–deficient fibroblasts were 
small and spindled shaped, contained reduced amounts of polymerized actin and migrated 
poorly. In K-RASG12D–expressing fibroblasts, inactivation of Pggt1b caused cell rounding 
and proliferation arrest, but not apoptosis. Pggt1bΔ/ΔK-RASG12D cells also accumulated in the 
G1 phase of the cell cycle, but expressed normal levels of p21
CIP1. However, Pggt1b 
inactivation prevented the K-RASG12D–induced increase in Cyclin D1, a protein implicated 
in cell cycle progression [227]. Finally, coexpression of farnesylated mutants of RHOA and 
CDC42 in Pggt1bΔ/ΔK-RASG12D fibroblasts prevented cell rounding and partially restored 
proliferation. Expression of only farnesylated RHOA or only farnesylated CDC42 did not 
restore these effects. 
Cre-adenovirus treatment of Fntbfl/flPggt1bfl/fl fibroblasts induced accumulation of K-RAS in 
the cytosol, indicating loss of isoprenylation. However, the FntbΔ/ΔPggt1bΔ/Δ fibroblasts 
underwent apoptosis and died within a few days (figure 7C, page 36).  
We used western blots to analyse the impact of inactivating Fntb or Pggt1b on the activation 
of RAS effectors. Fntb inactivation in normal fibroblasts did not affect levels of 
phosphorylated MEK or ERK, but delayed serum-induced activation of phosphorylated AKT. 
Inactivation of Pggt1b resulted in a minor decrease of phosphorylated ERK in normal 
fibroblasts, but did not affect phosphorylated ERK in K-RASG12D-expressing fibroblasts. 
Levels of phosphorylated AKT increased slightly as a consequence of Pggt1b inactivation in 
both normal and K-RASG12D–expressing fibroblasts. Thus, inactivating Fntb or Pggt1b had 
only minimal effects on signaling through the classical RAS pathways. 
Inactivation of Fntb or Pggt1b  reduced  lung  tumor growth and prolonged 
survival,  and  the  simultaneous  inactivation  of  Fntb  and  Pggt1b  further 
improved phenotypes 
In paper I, we developed a mouse model of K-RAS–induced cancer, by breeding mice 
harboring the Cre-inducible KLSL allele with LC mice. Since LC mice had been used in the 
past to yield myeloid-specific Cre expression, we hypothesized that the KLSLLC mice would 
develop a myeloid malignancy. Although KLSLLC mice displayed some mild 
myeloproliferative phenotypes, the most dramatic phenotype was a rapidly progressing lung 
cancer. KLSLLC mice developed diffuse hyperplasia, adenomas and adenocarcinomas that 
compressed and obliterated lung alveoli, resulting in a 10-fold increase in lung weight 
compared to lung weight of healthy, control mice (figure 8A, page 38). The lung cancer was 
lethal within three weeks of age (figure 8B, page 38). We showed that oncogenic K-RASG12D 
was expressed not only in myeloid cells, but also in type II pneumocytes, which is supported 
by data in the literature and explains the development of lung cancer.  
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To determine the impact of GGTase-I deficiency on lung tumor development, KLSLLC mice 
were bred on a background of homozygosity for the conditional GGTase-I knockout allele 
(i.e., Pggt1bfl/flKLSLLC). In the lung cells of these mice, Cre recombinase simultaneously 
activated oncogenic K-RASG12D and inactivated Pggt1b. We showed that inactivation of 
Pggt1b reduced formation of lung tumors and dramatically prolonged survival (figure 8A-B). 
Figure 8 includes data from additional KLSLLC and Pggt1bfl/flKLSLLC mice that were studied 
after the publication of paper I. 
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Figure 8. Inactivation of Pggt1b and/or Fntb reduced lung tumor development and prolonged lifespan of 
KLSLLC mice. (A) Lung weight in 3-week-old healthy control (Ctr, n=16), KLSLLC (n=27), Fntbfl/ΔKLSLLC (-
FTase, n=7), Pggt1bfl/flKLSLLC (-GGTase-I, n=13) and Fntbfl/ΔPggt1bfl/ΔKLSLLC (-FTase, -GGTase-I, n=6) 
mice. (B) Kaplan-Meier curve showing survival of KLSLLC (n=12), Fntbfl/ΔKLSLLC (-FTase, n=16), 
Pggt1bfl/flKLSLLC (-GGTase-I, n=22) and Fntbfl/ΔPggt1bfl/ΔKLSLLC (-FTase, -GGTase-I, n=10) mice.  
In paper II, we determined the impact of FTase deficiency on the development of K-RAS–
induced lung cancer using the same model as in paper I. Thus, KLSLLC mice were bred on an 
Fntbfl/Δ background. Fntbfl/ΔKLSLLC mice had a reduced lung tumor burden, revealed by 
histological analyses and lung weight, and lived significantly longer than KLSLLC mice 
(figure 8A-B). FTase and GGTase-I deficiency reduced lung tumors to a similar extent and 
there was no difference in survival of the Fntbfl/ΔKLSLLC and Pggt1bfl/flKLSLL mice 
(P=0.051, Pggt1bfl/flKLSLLC vs. Fntbfl/ΔKLSLLC). Notably, Fntbfl/ΔLC mice were viable and 
had normal lung histology. 
The next goal was to define the impact of inactivating Fntb and Pggt1b on the development of 
K-RAS–induced lung cancer. In the KLSLLC lung cancer model, simultaneous inactivation of 
Fntb and Pggt1b dramatically reduced tumor load and improved survival. At three weeks of 
age, Fntbfl/ΔPggt1bfl/ΔKLSLLC mice (lacking FTase and GGTase-I in the lung) displayed 
normal lung histology and lung weights (figure 8A). Western blot analysis showed markedly 
lower levels of phosphorylated ERK in lung lysates from Fntbfl/ΔPggt1bfl/ΔKLSLLC mice 
than in lung lysates from KLSLLC mice. The Fntbfl/ΔPggt1bfl/ΔKLSLLC mice lived much 
longer than KLSLLC mice (median 170 days vs. 22 days, P<0.0001), despite wide-spread 
expression of K-RASG12D. However, the mice eventually developed lung tumors and had to 
be euthanized (figure 8B).   
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We detected lung cells that lacked both FTase and GGTase-I activity in 3-week-old 
Fntbfl/ΔPggt1bfl/ΔKLSLLC mice. Western blots of lung extracts showed a small proportion of 
N-RAS (~5%) with reduced electrophoretic mobility, characteristic of nonprenylated N-RAS, 
indicating the presence of at least some cells lacking both FTase and GGTase-I (figure 9A). In 
addition, cells that stained for both Prelamin A and np-RAP1A (markers of absent FTase and 
GGTase-I activity, respectively) were detected in lung sections from 3-week-old 
Fntbfl/ΔPggt1bfl/ΔKLSLLC mice (figure 9B).  
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Figure 9. Simultaneous inactivation of Fntb and Pggt1b inhibited isoprenylation of N-RAS and appeared 
to be compatible with viability of lung cells. (A) Western blots of lung extracts from 3-week-old KLSLLC and 
Fntbfl/ΔPggt1bfl/ΔKLSLLC mice, incubated with an antibody against N-RAS. Notice the slower migrating form 
of N-RAS in the Fntbfl/ΔPggt1bfl/ΔKLSLLC extracts. ACTIN was used as loading control. (B) Prelamin A (red, 
nucleus) and np-RAP1A (green, cytoplasmic) expression in lungs from 3-week-old Fntbfl/ΔPggt1bfl/ΔKLSLLC 
(upper panel) and Fntbfl/ΔPggt1bfl/ΔLC mice (lower panel), detected by confocal microscopy. Nuclei were 
stained with DAPI (blue).   
We also detected lung cells that were positive for only Prelamin A or np-RAP1A or negative 
for both. We hypothesized that the lung tumors that eventually developed in 
Fntbfl/ΔPggt1bfl/ΔKLSLLC mice were derived from such cells: i.e. expressing K-RASG12D, 
but with incomplete recombination of Fntb and/or Pggt1b alleles. Indeed, quantitative PCR 
analysis of lung tumors isolated from old Fntbfl/ΔPggt1bfl/ΔKLSLLC mice confirmed that the 
majority of tumor cells had a recombined KLSL allele, thus expressing oncogenic K-RAS, but 
unrecombined Fntb and/or Pggt1b alleles. This was in contrast to the lung tumors in 
Pggt1bfl/ΔKLSLLC, described in paper I, in which both Pggt1b alleles were recombined.   
Importantly, Fntbfl/ΔPggt1bfl/ΔLC mice were viable and had normal lung weights and 
histology. Also in these mice, some lung cells stained for both Prelamin A and np-RAP1A, 
suggesting that normal lung cells were viable in the absence of isoprenylation (figure 9B).  
In addition, simultaneous inactivation of Fntb and Pggt1b inhibited tumorigenesis in a second 
K-RAS–induced lung tumor model. Cre-adenovirus was intranasally administered to KLSL 
and Fntbfl/ΔPggt1bfl/ΔKLSL mice and 8 weeks later tumor number and size were determined. 
Cre-treated KLSL mice had many large tumors that were visible on the lung surface. In 
comparison, the Cre-treated Fntbfl/ΔPggt1bfl/ΔKLSL mice showed a 76% reduction in tumor 
number and a 79% reduction in tumor size.  
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GGTase­I deficiency was well  tolerated  in myeloid cells and eliminated K­
RAS–induced myeloproliferative phenotypes  
Finally, in paper I, we did not only show that fibroblasts and lung tumor cells were viable in 
the absence of GGTase-I, but also macrophages and CFU-GM colony-forming hematopoietic 
cells. In addition, inactivation of Pggt1b eliminated all myeloproliferative phenotypes of 
KLSLLC mice, such as elevated levels of neutrophils in the blood, infiltration of myeloid cells 
in the liver and autonomous colony formation of K-RASG12D−expressing hematopoietic cells.  
In summary, the results in Paper I and II showed that inactivating either FTase or GGTase-I, 
or both enzymes, reduced tumor development in mice with K-RAS–induced lung cancer.   
Nf1 deficiency cooperates with oncogenic K-RAS to induce acute 
myeloid leukemia in mice (Paper III) 
The aim of this paper was to define the impact of Nf1 deficiency on K-RAS–induced MPD. 
To approach this issue, we bred Nf1 conditional knockout mice (Nf1fl/fl; designated N) with 
KLSL mice (designated K) and mice harboring the interferon-inducible Mx1-Cre transgene 
(designated M). Injection of pI-pC into the “NKM” mice simultaneously induced expression 
of K-RASG12D and inactivation of Nf1 in hematopoietic cells. NKM mice were compared 
with MPD control mice (KM and NM) and healthy control mice (Ctr).  
We showed that NKM mice developed a myeloid malignancy with a reduced latency and 
increased severity compared to KM and NM mice. Nf1 deficiency in the setting of oncogenic 
K-RASG12D expression dramatically increased the total number of white blood cells and the 
number of immature cells, including myeloblasts (figure 10A and B).  Furthermore, the NKM 
mice became anemic and they had a much shorter life span than KM mice (P < 0.0001) 
(figure 10C). 
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Figure 10. NKM mice developed a rapidly fatal myeloid malignancy, with a large number of immature 
white blood cells in the blood. (A) White blood cell counts of NKM, KM, NM and Ctr mice. *** P < 0.001. (B) 
Photographs of typical blood smears from NKM, KM, NM and Ctr mice three weeks after pI-pC injection. 
Arrowheads point to myeloblasts. (C) Kaplan-Meier curve showing survival of NKM, KM, NM and Ctr mice. 
NKM mice displayed a higher degree of myeloid cell infiltration in liver and spleen compared 
to KM and NM mice, and the weights of these organs were dramatically increased. In 
addition, NKM splenocytes had an increased proportion of surface markers for immature 
myeloid cells (Cd11b+/Gr1+, CD34, CD117; determined by FACS analysis) and produced 
more colonies in methylcellulose both in the absence and presence of growth factors, 
compared with MPD control mice. Finally, the NKM disease was transplantable. 
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Bone marrow cells from pI-pC injected NKM mice were injected into sublethally irradiated 
recipient mice. All 6 recipients became moribund by 12 weeks after transplantation and three 
of them had high white blood cell counts and splenomegaly. 
Thus, the results showed that the NKM mice developed AML. AML in mice is classified 
based on the following criteria: increased number of nonlymphoid hematopoietic cells in 
spleen and bone marrow, anemia, spreading of neoplastic cells (leukocytosis and 
nonlymphoid infiltration in the liver), >20% immature cells in peripheral blood, and rapid 
fatality in primary animals [170]. 
Levels of RAS-GTP (active RAS) were not higher in bone marrow cells from NKM mice than 
in bone marrow cells from KM mice (figure 11A). Similar results were seen in Cd11b+ 
hematopoietic cells (figure 11B). These results indicated that mechanisms unrelated to 
enhanced activation of RAS contributed to the progression of MPD (KM mice) into AML 
(NKM mice). 
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Figure 11. RAS-GTP levels were similar in hematopoietic cells from NKM and KM mice. (A) Western blots 
of extracts from serum-starved and GM-CSF stimulated bone marrow cells from NKM, KM, NM and Ctr mice. 
(B) Western blots of extracts from serum-starved and GM-CSF stimulated Cd11b+ cells from NKM, KM and Ctr 
mice. ACTIN was used as loading control. Band densities were determined and displayed as ratios.  
In summary, the results described in paper III showed that Nf1 deficiency cooperated with 
oncogenic K-RAS and that the two mutations induced AML in mice.  
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DISCUSSION 
Paper I showed that inactivation of Pggt1b blocked proliferation and reduced migration of 
fibroblasts. Furthermore, inactivating Pggt1b reduced tumor development and improved 
survival of mice with K-RAS–induced lung cancer. In Paper II, we showed that inactivation 
of Fntb prevented membrane targeting of H-RAS and arrested proliferation of fibroblasts. 
Fntb inactivation also improved survival and reduced tumor growth in mice with K-RAS–
induced lung cancer. Simultaneous inactivation of Fntb and Pggt1b potentiated the antitumor 
effect. In Paper III, we showed that Nf1 deficiency and oncogenic K-RAS cooperated to 
induce AML in mice.  
The importance of validating conditional knockout alleles   
Our findings regarding the consequences of Fntb inactivation differ significantly from 
Mijimolle’s previously published findings using another conditional Fntb knockout allele 
[33]. In the latter study, it was suggested that Fntb inactivation only partially inhibited 
isoprenylation of HDJ2 and did not prevent membrane targeting of H-RAS. Also, Mijimolle 
et al. reported that Fntb-deficient fibroblasts could grow in culture. Finally, inactivation of 
Fntb had no significant effect on lung tumor initiation in mice with endogenous expression of 
K-RASV12. Although the reason for these discrepancies is not know, a potential explanation is 
that excision of the floxed exon 3 in Mijimolle’s Fntb allele resulted in an unexpected 
splicing event. Characterization of the transcripts from the mutant allele showed that the 
dominant transcript lacked both exon 3 and 4 sequences; this transcript is predicted to encode 
a protein with an in-frame deletion, which may retain partial function [228].  
Thus, when using Cre/loxP techniques to create a conditional knockout allele, it is crucial to 
validate that the recombination event results in an actual null allele. It is important that this is 
done by both documenting recombination within the genomic DNA and through analysis of 
transcripts [228]. We validated our conditional FTase knockout allele by showing that Cre 
recombination deleted the promoter and exon 1 and blocked Fntb expression: no transcripts 
were detected from the Fntb null allele.   
Incomplete recombination ­ a potential limitation of knockout strategies  
One potential limitation with conditional gene targeting is the possibility of incomplete 
recombination. For example, partial recombination in Fntbfl/flKLSL cells would produce 
Fntbfl/ΔKG12D cells, expressing K-RASG12D but also FTase, due to an unrecombined Fntbfl 
allele. We developed quantitative PCR assays to monitor for partial recombination. The 
quantitative PCR assays quantified recombination of the KLSL, Fntbfl and Pggt1bfl alleles and 
were performed on genomic DNA isolated from cells and tissues. In addition, recombination 
of the Fntbfl and Pggt1bfl alleles were determined by western blots and immunofluorescence, 
using antibodies to various CAAX protein substrates as markers of FTase and/or GGTase-I 
deficiency. Moreover, in paper II, we minimized the risk of partial recombination, by using 
mice harboring one null allele of Fntb and/or Pggt1b (e.g. Fntbfl/ΔKLSLLC mice).  
In paper I, we used quantitative PCR to show that both Pggt1bfl alleles were recombined in 
80-90% of myeloid cells and in cells isolated from lung tumors. Recombination of the Fntbfl 
allele was determined by using the characteristic that nonfarnesylated HDJ2 and H-RAS 
migrate slower in SDS-PAGE gels than their farnesylated counterparts. In this way, it was 
confirmed that both Fntbfl alleles were recombined in fibroblasts; in vivo, approximately 50% 
of HDJ2 in lung extracts from Fntbfl/ΔKLSLLC mice migrated slower. 
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To detect cells with recombined Fntbfl and Pggt1bfl alleles, we performed western blots with 
antibodies against K-RAS and N-RAS, which display a retarded electrophoretic mobility 
when they are nonprenylated. In addition, by using confocal microscopy and 
immunofluorescence, we detected cells that stained for Prelamin A and/or np-RAP1A. 
Although a portion of cells stained positive for both Prelamin A and np-RAP1A in lung tissue 
from 3-week-old Fntbfl/ΔPggt1bfl/ΔKLSLLC  mice, other cells stained positive for only 
Prelamin A or np-RAP1A or were negative for both markers. Fntbfl/ΔPggt1bfl/ΔKLSLLC mice 
eventually developed tumors and we suspect that these were formed by cells with 
unrecombined Fntbfl and/or Pggt1bfl alleles. Indeed, quantitative PCR analysis of lung tumor 
DNA isolated from Fntbfl/ΔPggt1bfl/ΔKLSLLC mice confirmed incomplete recombination of 
Fntbfl and/or Pggt1bfl alleles.  Despite this, Fntbfl/ΔPggt1bfl/ΔKLSLLC mice lived much 
longer than KLSLLC mice. 
What proteins are responsible for the antitumor effects of inactivating Fntb 
and Pggt1b? 
The absence of FTase or GGTase-I reduced tumor development induced by oncogenic K-
RAS, despite the fact that the isoprenylation of K-RAS was unaffected. This implies that the 
observed antitumor effects are due to inhibition of isoprenylation of CAAX proteins other than 
K-RAS. Perhaps this could also explain the minor effects of Fntb or Pggt1b inactivation on 
the RAS downstream effectors MEK and ERK. In normal fibroblasts, phosphorylated 
(activated) ERK was not reduced by inactivating Fntb and only a minor decrease was seen 
when inactivating Pggt1b.  
There are more than 50 geranylgeranylated proteins in human cells [3], which are all potential 
candidates for mediating the antitumor effects of Pggt1b inactivation. Similarly to most 
GGTI-treated cells, cell cycle arrested Pggt1bΔ/Δ fibroblasts exhibited increased levels of 
p21CIP1. Increased p21CIP1 levels have been suggested to be a consequence of inhibiting 
geranylgeranylation of RHOA; therefore we hypothesized that RHOA may be an important 
target. However, Pggt1b inactivation in K-RASG12D–expressing fibroblasts did not affect 
p21CIP1. The explanation for this is not known. But GGTIs can also induce a G1 cell cycle 
arrest in some tumor cell lines without increasing p21CIP1 [115]. Moreover, reduced 
polymerized actin and impaired migration of Pggt1bΔ/Δ fibroblasts suggested involvement of 
proteins regulating actin cytoskeleton, such as RHOA and CDC42.  
To test if geranylgeranylation of RHOA and CDC42 was important for cell proliferation, cell 
cycle arrested Pggt1b-deficient fibroblasts expressing K-RASG12D were transfected with 
farnesylated mutants of RHOA (fRHOA) and CDC42 (fCDC42). The fact that expression of 
neither fRHOA nor fCDC42 alone could restore cell proliferation of these cells is consistent 
with a study showing that farnesylation of RHOA did not prevent GGTI-mediated growth 
inhibition [134]. However, coexpression of fRHOA and fCDC42 prevented cell rounding and 
could temporarily restore the proliferation of Pggt1b-deficient fibroblasts expressing K-
RASG12D. This indicates that RHOA and CDC42 are the GGTase-I substrates that are crucial 
for cell proliferation. However, we cannot rule out the possibility that some GGTase-I 
substrates undergo alternative isoprenylation by FTase. Also, the Pggt1bΔ/ΔKG12D cells 
transfected with fRHOA and fCDC42 stopped growing after a while, which indicates that 
other GGTase-I substrates are required for maintaining cell proliferation.  
Also, it has been shown earlier that expressing farnesylated versions of RAC and RAL 
proteins can make cells resistant to different antitumor effects of GGTIs. These studies 
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suggest that geranylgeranylation of RAC1 and RAC3 is important for transformation [137], 
and that geranylgeranylation of RALA and RALB is important for cell growth and survival 
[148].  
Similar to GGTase-I, FTase has more than 50 cellular substrates and the antitumor effects of 
inactivating Fntb may be explained by the inhibition of the proper function of any of these 
CAAX proteins [3]. The G2/M cell cycle arrest of our Fntb-deficient fibroblasts may be 
explained by inhibition of the mitotic proteins CENP-E and CENP-F. This would be 
supported by FTI studies showing that inhibiting farnesylation of CENP-E and CENP-F 
disrupts chromosomal maintenance and results in mitotic delay [101]. Also, farnesylation of 
CENP-F has been shown to be required for cells to progress through G2/M [102].  
FTI studies have also suggested RHEB and PRL proteins to be important targets. In 
Schizosaccharomyces pombe, the cell cycle defect caused by FTase deficiency was reversed 
by expressing a geranylgeranylated form of RHEB [36, 98]. Expression of geranylgeranylated 
RHEB could also prevent the enhanced apoptotic response to chemotherapeutics mediated by 
FTI treatment [100]. Moreover, inhibiting farnesylation of H-RAS, which does not undergo 
alternative isoprenylation by GGTase-I, may have antitumor effects also in tumors caused by 
K-RAS mutations. Indeed, wild-type H-RAS and N-RAS have been shown to be required for 
initiating and maintaining growth of K-RAS–induced tumors [229].  
Although the studies above indicate that some CAAX proteins may be particularly important, 
the antitumor effects of inactivating Fntb or Pggt1b are likely a result of inhibiting several 
CAAX proteins. Our Fntbfl/fl and Pggt1bfl/fl fibroblasts are valuable tools for identifying these 
substrates. Since Cre recombination results in a cell cycle arrest in these cells, they can be 
used to test what proteins are crucial for cell proliferation. We plan to transfect Fntbfl/fl 
fibroblasts with geranylgeranylated mutants of CENP-E and CENP-F and subsequently infect 
them with Cre-adenovirus. If geranylgeranylated CENP-E or/and CENP-F rescue cell 
proliferation, these proteins are required for cell cycle progression. Similarly, we plan to 
define whether farnesylated versions of RAC1 and RAC3 reverse the phenotypes of our 
Pggt1b-deficient fibroblasts. Other suggested FTI and GGTI targets may be tested in the same 
way. 
Similar strategies could be used to produce knock-in mice, replacing genes encoding FTase or 
GGTase-I substrates by sequences mutated to express geranylgeranylated and farnesylated 
versions of the same proteins, respectively. We are in the process of generating a knock-in 
mouse that express farnesylated RHOA. This mouse will be valuable for evaluating the role 
of RHOA in mediating effects of Pggt1b inactivation in vivo.  
The enhanced antitumor effect of simultaneously inactivating Fntb and Pggt1b may be 
explained by the inhibition of several farnesylated and geranylgeranylated CAAX proteins; 
and/or by inhibition of CAAX proteins that can be substrates for both enzymes. K-RAS is of 
course an obvious target; inhibition of isoprenylation and membrane association of K-RAS 
may contribute to the enhanced antitumor effect. In our study (Paper II), K-RAS 
isoprenylation was inhibited in Fntb/Pggt1b-deficient fibroblasts (lacking both Fntb and 
Pggt1b), at least to a certain extent: a substantial portion of K-RAS accumulated in the 
soluble protein fraction and had a slower electrophoretic mobility. In contrary to the effect of 
inactivating Fntb alone or Pggt1b alone, western blots of lung extracts showed that 
inactivating both Fntb and Pggt1b dramatically decreased levels of phosphorylated ERK. This 
implicates that reduced signaling through the RAS-RAF-MEK-ERK pathway may contribute 
significantly to the observed antitumor effects. As discussed earlier, disrupting activation of 
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wild-type N-RAS may also result in antitumor effects. Along this line, a small proportion of 
lung cells in vivo contained nonprenylated N-RAS.  
Furthermore, Fntb/Pggt1b-deficient cells should also fail to isoprenylate CAAX proteins that 
normally exist in both farnesylated and geranylgeranylated forms, such as RHOB and RHOH. 
RHOB, as well as RHOH, which may be specific for hematopoietic cells, act as tumor 
suppressors [155]. Therefore, inhibition of RHOB and RHOH may rather promote than inhibit 
tumorigenesis. However, given the increased antitumor effect of blocking both FTase and 
GGTase-I, these proteins may play a minor role in cancer development, at least in lung 
cancer.  
Will inhibition of FTase and/or GGTase­I be associated with toxicity? 
FTIs have been shown to be remarkably well tolerated in mice and in humans [36, 82].  
Similarly, we showed that Fntbfl/ΔLC mice, with Fntb-deficient myeloid cells and lung cells, 
were healthy and fertile and did not display any apparent pulmonary abnormalities.  In vivo 
use of GGTIs has raised concerns about severe toxicity [123], even if some studies have 
suggested that GGTIs may not be particularly toxic [118, 124-126]. Pggt1bfl/flLC mice were 
fertile and appeared healthy, with normal lung histology and normal white blood cell counts. 
Furthermore, several cell types were viable in the absence of Pggt1b, including lung tumor 
cells and macrophages. 
The data about toxicity of combined FTI/GGTI treatment in vivo are conflicting. In some 
xenograft models, no animal toxicity was reported [93, 122], while other FTI/GGTI 
combinations and DPIs were lethal in mice [123]. We showed that the simultaneous 
inactivation of Fntb and Pggt1b resulted in cell death in fibroblasts, while inactivation of both 
genes in lung cells appeared to be well tolerated. Despite their lung tumors, 
Fntbfl/ΔPggt1bfl/ΔKLSLLC  and Fntbfl/ΔPggt1bfl/ΔKLSL mice looked healthy for several 
months. Furthermore, no obvious abnormalities were found in lungs from 
Fntbfl/ΔPggt1bfl/ΔLC mice. However, as judged by immunofluorescence, several lung cells in 
these mice expressed either FTase or GGTase-I or both, while relatively few cells were 
deficient in both enzymes. This may indicate that Fntb/Pggt1b-deficient lung cells are more 
susceptible to cell death. In the ongoing revision of paper II, we assess if any apoptosis can be 
detected in lung cells of the Fntbfl/ΔPggt1bfl/ΔLC mice.  
Since we inactivated Fntb and/or Pggt1b in a cell type-specific manner, we still know 
relatively little about toxicity of FTase and/or GGTase-I deficiency in other cell types, organs 
or whole animals. Furthermore, we have not assessed long term toxicity of inactivating Fntb 
and/or Pggt1b. To define the utility of inhibiting FTase and/or GGTase-I as an anti-cancer 
strategy, assessment of organ and whole body toxicity is crucial. To address this question, 
Fntbfl/fl and Pggt1bfl/fl mice could be bred with mice harboring different cell type-, tissue-
specific, or ubiquitous Cre transgenes. 
Fntbfl/fl and Pggt1bfl/fl mice will be useful in many kinds of studies 
As discussed earlier, Fntbfl/fl and Pggt1bfl/fl fibroblasts and mice are valuable tools for 
identifying FTase and GGTase-I substrates that are important for the antitumor activities of 
FTIs and GGTIs. The conditional knockout mice may also be bred with cell type-specific Cre 
mice, to study the functional importance of FTase and GGTase-I in different cell types. 
Similarly, the tolerability of FTase and/or GGTase-I deficiency in different organs can be 
defined. Fntbfl/fl and Pggt1bfl/fl mice can also be used to define the effects of FTase and/or 
GGTase-I deficiency on the development of other cancers, including cancer not initiated by 
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oncogenic RAS. Furthermore, Fntbfl/fl and Pggt1bfl/fl mice can be used to study the 
importance of protein farnesylation and geranylgeranylation in various other diseases. Finally, 
the Fntbfl/fl and Pggt1bfl/fl mice can be used to elucidate which effects of FTIs and GGTIs 
that are due to enzymatic inhibition and which are due to off-target effects.  
The importance of Nf1 deficiency in K­RAS–induced cancer 
In Paper III, we showed that simultaneous inactivation of Nf1 and expression of oncogenic K-
RAS in hematopoietic cells induced AML. This was unexpected, since Nf1 deficiency has 
been viewed as functionally equivalent with an oncogenic RAS mutation.  
Potentially, the AML phenotype may be caused by hyperactive RAS signaling per se, since 
Nf1 deficiency may increase levels of GTP-bound N-RAS and H-RAS. However, we showed 
by western blots that RAS-GTP levels in hematopoietic cells (total bone marrow and CD11b+ 
cells) of NKM mice were not elevated compared to KM mice. This data supports that RAS-
independent functions of NF1 contribute to the AML in NKM mice.  
NFI has been suggested to have other functions than RAS-GAP activity. Actually, many 
mutations found in NF1 patients occur outside the GAP-related domain [70, 194, 197]. 
Particularly interesting is the potential involvement of NF1 in the cyclic AMP-PKA pathway 
described in Drosophila [200, 201]. NF1 has also been shown to regulate the actin 
cytoskeleton in a RAS-independent way, by acting as a negative regulator of the RAC1/PAK1 
pathway [230]. Moreover, Guo et al. suggested that NF1 may function as an effector that 
mediates signaling important for differentiation [199]. Therefore, it could be speculated that 
loss of NF1 impairs differentiation, thereby providing “the second hit” by which the RAS-
mediated MPD progresses into AML. Another potential explanation for the cooperation 
between Nf1 deficiency and RAS signaling could be that NF1 functions as a GAP for 
GTPases other than RAS, which may be involved in signaling pathways regulating cellular 
differentiation.  
We have planned to determine if the cooperation of Nf1 deficiency and oncogenic K-RAS is 
caused by the loss of the RAS-GAP activity or if it is related to a RAS-GAP–independent 
function of NF1. We will infect NKM fetal liver cells with a lentivirus expressing either the 
RAS-GAP domain of NF1 or a full length NF1 with mutations in the RAS-GAP domain, and 
then inject the transduced cells into lethally irradiated mice. After repopulation, we will inject 
pI-pC to induce development of AML. If the RAS-GAP domain can prevent the MPD from 
developing into an AML, we can conclude that it is the loss of the RAS-GAP activity of NF1 
that contributes to the development of AML. Similarly, if the full length NF1 with the 
mutated RAS-GAP domain restores the MPD, we can conclude that RAS-GAP–independent 
functions of NF1 are important for progression into AML. We plan to perform similar 
experiments with dominant negative and constitutively active PKA, to determine if PKA 
might be involved in the cooperation between Nf1deficiency and oncogenic K-RAS.  
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CONCLUSIONS 
In this thesis I used genetic strategies in mice to define the importance of isoprenylation and 
Nf1 deficiency in K-RAS–induced cancer. I can now conclude the following: 
• Inactivation of FTase and/or GGTase-I reduced the development of K-RAS–induced 
cancer in mice.  
This result validates the idea of targeting FTase and/or GGTase-I as an anti-cancer 
strategy. However, to conclude that FTase and GGTase-I are suitable drug targets the 
potential toxicity of inhibiting these enzymes must be further evaluated. 
• Nf1 deficiency cooperated with oncogenic K-RAS to induce AML in mice.  
Contrary to our expectations, simultaneous inactivation of Nf1 and expression of oncogenic 
K-RAS in hematopoietic cells induced AML in mice. Future experiments are planned to 
define the mechanisms behind this cooperation. 
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